# Chapter 106: Other Hallucinogen Intoxication

Here is the comprehensive academic chapter on the biological and neurological basis of Other Hallucinogen Intoxication, citing exclusively from the provided research papers.

# Chapter: The Biological and Neurological Basis of Other Hallucinogen Intoxication

## Introduction

Other Hallucinogen Intoxication represents a complex neuropsychiatric syndrome characterized by profound alterations in perception, mood, and cognition following the administration of a hallucinogenic substance (Pechnick et al., 2014). These psychoactive drugs, also known as psychedelics, are a broad and heterogeneous class of agents that alter consciousness without necessarily producing delirium, sedation, or excessive stimulation (Iversen et al., 2009; Pechnick et al., 2014). The experience of intoxication can range from euphoria and transcendent states to severe anxiety, panic, and psychotic reactions (Cole & Katz, 1964; Rastegar & Fingerhood, 2015). From a biological perspective, understanding this condition requires an examination of the intricate interplay between the specific pharmacological properties of these substances and the underlying neurobiology of the human brain.

The substances categorized under this heading are diverse, including classic serotonergic hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and mescaline; anticholinergic deliriants found in plants like jimsonweed; and a growing number of synthetic or "designer drugs" (Pechnick et al., 2014; Rastegar & Fingerhood, 2015). While some substances, such as phencyclidine (PCP) and ketamine, are often classified separately as dissociative anesthetics, they share many phenomenological characteristics with hallucinogens and are frequently considered in the same context of substance-induced mental disorders (Rastegar & Fingerhood, 2015; Rastegar, 2020). The hallmark of hallucinogen intoxication is the capacity to induce states of altered or distorted perception, thought, and mood, which can manifest as illusions, synesthesias, and true hallucinations (Williams & Erickson, 2000; Iversen et al., 2009). These experiences are not merely sensory but are often accompanied by intense and rapidly shifting emotional states, ranging from mystical elation to severe depression or panic (Cole & Katz, 1964).

The clinical presentation of hallucinogen intoxication can be highly variable, depending on the specific drug, dosage, and the user's expectations and environment (Pechnick et al., 2014). In some cases, the experience resembles a model psychosis, providing a window into the potential neurobiological underpinnings of disorders like schizophrenia (Cole & Katz, 1964; Iversen et al., 2009). Indeed, the use of terms like "psychotomimetic" underscores this historical association (Pennes & Hoch, 1957; Isbell, 1956). In severe cases, intoxication can manifest as a toxic psychosis, delirium, or an acute confusional state, characterized by disturbances in consciousness, attention, and global cognitive impairment (Schildkrout, 2014; Lipowski, 1987). These severe reactions can be difficult to distinguish from primary psychotic disorders or other organic mental syndromes (Mauri, 2016; Griswold et al., 2015).

This chapter will provide a comprehensive overview of the biological and neurological basis of Other Hallucinogen Intoxication. It will explore the neuropharmacological mechanisms through which these substances exert their effects, focusing on key neurotransmitter systems. Furthermore, it will examine the implicated brain regions and neural circuits, drawing on findings from functional neuroimaging and neuropathology in related conditions. The discussion will extend to cellular and synaptic mechanisms, genetic predispositions that may influence individual responses, and the neurodevelopmental context, particularly the heightened vulnerability of the adolescent brain (Hyytiä, 2015). Finally, the chapter will address the biological heterogeneity of these disorders and the implications of our neurobiological understanding for the development of targeted treatment strategies. The aim is to synthesize the available evidence to construct a coherent biological model of hallucinogen intoxication, while acknowledging the significant gaps that remain in our knowledge (Rastegar & Fingerhood, 2015).

## Neurobiological Systems

The profound psychological effects of hallucinogen intoxication are rooted in the disruption of multiple neurobiological systems. The specific constellation of symptoms—from perceptual distortions and hallucinations to emotional lability and cognitive changes—is a direct consequence of the drug's interaction with specific neurotransmitter pathways and neural circuits (Willner, 1984). While the substances are heterogeneous, distinct patterns of neuropharmacological action can be identified that correspond to different classes of hallucinogens and their associated intoxication syndromes (Rastegar & Fingerhood, 2015; Pechnick et al., 2014).

### Neurotransmitter Systems and Neuropharmacology

The primary mechanism of action for most classic hallucinogens involves the modulation of neurotransmitter systems, particularly the serotonergic, dopaminergic, glutamatergic, and cholinergic pathways (Iversen et al., 2009; Latt et al., 2009).

**The Serotonergic System:** The most widely studied hallucinogens, including LSD, psilocybin, and mescaline, are often characterized as "serotonergic hallucinogens" due to their predominant effect on the serotonin (5-hydroxytryptamine, 5-HT) system (Pechnick et al., 2014). The psychedelic effects of these drugs are primarily mediated through their agonist or partial agonist activity at serotonin 5-HT2A receptors (5-HT2AR) (Latt et al., 2009; Jalal, 2018). Activation of these receptors, which are densely expressed in cortical and limbic regions, is thought to underlie the profound changes in perception, thought, and mood that define the psychedelic experience (Latt et al., 2009; Scotton et al., 2019). The striking similarity between the perceptual experiences induced by hallucinogenic drugs and the "ghost-like" hallucinations of sleep paralysis has led to the hypothesis that 5-HT2AR activation is a common neuropharmacological pathway for these phenomena (Jalal, 2018). Excessive serotonergic activity can lead to a potentially life-threatening condition known as serotonin syndrome or serotonin toxicity, which presents with a triad of altered mental status (agitation, confusion), autonomic hyperactivity (hyperthermia, tachycardia), and neuromuscular abnormalities (tremor, clonus, hyperreflexia) (Scotton et al., 2019; Gordon & Leder, 2012). This syndrome can be precipitated by an overdose of a single serotonergic agent or, more commonly, by a combination of drugs that increase serotonergic transmission, such as a selective serotonin reuptake inhibitor (SSRI) and a monoamine oxidase inhibitor (MAOI) (Yates et al., 2011; Scotton et al., 2019). The clinical overlap between severe hallucinogen intoxication and serotonin syndrome underscores the central role of the 5-HT system (Rahmani, 2011). Furthermore, drugs that block serotonin reuptake, such as venlafaxine, can also be associated with adverse psychiatric effects, including mania and suicidal ideation, highlighting the system's role in mood regulation (Hefzi et al., 2019; Todder & Baune, 2007).

**The Dopaminergic System:** The dopamine (DA) system is critically involved in reward, motivation, and the modulation of psychosis (Willner, 1984; Dodd, 2007). Hallucinogen-induced psychosis, characterized by paranoia, delusions, and hallucinations, shares phenomenological similarities with primary psychotic disorders like schizophrenia (Mauri, 2016; Cole & Katz, 1964). This has led to the hypothesis that hallucinogens may induce their psychotomimetic effects by disrupting dopaminergic neurotransmission, particularly via D2 receptors in mesolimbic pathways, mirroring the dopamine hypothesis of schizophrenia (Willner, 1984; Dodd, 2007; Volkow & Wolf, 1991). Stimulant drugs such as cocaine and amphetamines, which are known to cause psychotic symptoms, act by stimulating dopamine release or blocking its reuptake (Dodd, 2007; Snyder, 2019; Antonio & Alfredo, 2012). The fact that antipsychotic drugs, which are D2 receptor blockers, are effective in treating both schizophrenia and drug-induced psychosis further supports a common dopaminergic mechanism (Dodd, 2007; Volkow & Wolf, 1991; Marder, 2006). Some hallucinogens, like MDMA ("ecstasy"), cause the release of both serotonin and dopamine, contributing to their mixed stimulant and hallucinogenic properties (Patel et al., 2011; López‐Arnau et al., 2022). Chronic hallucinogen use may lead to neuroadaptive changes, such as dopamine receptor supersensitivity, which could underlie phenomena like spontaneous flashbacks or heightened vulnerability to stress-induced psychosis (Seeman & Seeman, 2011; Yui et al., 2006).

**The Glutamatergic System:** Dissociative anesthetics such as phencyclidine (PCP) and ketamine, which are often grouped with hallucinogens, produce their effects primarily by acting as non-competitive antagonists at the N-methyl-D-aspartate (NMDA) glutamate receptor (Hollister, 1990). The intoxication state is characterized by profound dissociative symptoms, including depersonalization, derealization, and amnesia, as well as analgesia and anesthesia at higher doses (Rastegar & Fingerhood, 2015; Winters, 1976). The psychosis induced by PCP can be particularly severe and prolonged, with symptoms of agitation, paranoia, and bizarre behavior that can be difficult to distinguish from schizophrenia (Jacob et al., 1981; Showalter & Thornton, 1977). The ability of NMDA antagonists to produce schizophrenia-like symptoms, including negative and cognitive deficits, has provided a powerful experimental model and has contributed to the development of glutamatergic hypotheses of schizophrenia (Rico, 2012).

**The Cholinergic System:** A distinct class of hallucinogens, known as deliriants, includes substances with anticholinergic properties, such as atropine and scopolamine, found in plants like jimsonweed (Datura stramonium) (Pechnick et al., 2014; Rastegar & Fingerhood, 2015). Intoxication with these agents blocks central muscarinic acetylcholine receptors, leading to a toxic psychosis known as the central anticholinergic syndrome (Schneck & Rupreht, 1989; Cook & Spence, 1997). This state is a classic delirium, characterized by confusion, disorientation, memory impairment, and vivid, often frightening, visual and auditory hallucinations (Schildkrout, 2014; Paetzold et al., 1999). Unlike serotonergic hallucinogens, which typically preserve a clear sensorium, anticholinergic intoxication is defined by a clouding of consciousness (Pechnick et al., 2014; Lipowski, 1987). The syndrome can be reversed by the administration of a centrally acting cholinesterase inhibitor like physostigmine, which increases the availability of acetylcholine in the brain (Schneck & Rupreht, 1989; Hasan & Mooney, 1979).

**The GABAergic System:** The gamma-aminobutyric acid (GABA) system is the primary inhibitory neurotransmitter system in the brain. Some hallucinogenic effects can be produced by GABA-enhancing agents, representing another distinct class of these drugs (Hollister, 1990). The mental states produced by these agents, such as muscimol, differ from those of classic hallucinogens and may involve more sedation and confusion (Hollister, 1990). Benzodiazepines, which enhance GABAergic transmission, are commonly used to manage the anxiety, agitation, and seizures that can occur during acute hallucinogen intoxication, highlighting the role of the GABA system in mitigating central nervous system hyperexcitability (Williams & Erickson, 2000; Marder, 2006). Conversely, withdrawal from GABAergic depressants like alcohol or benzodiazepines can lead to a state of CNS hyperexcitability, sometimes manifesting with hallucinations and delirium (Aubin et al., 1993; Hollister, 1977).

### Brain Regions, Neural Circuits, and Functional Connectivity

Hallucinogen intoxication involves the functional disruption of large-scale neural networks rather than isolated brain regions. The subjective experience of altered consciousness, ego-dissolution, and perceptual distortion reflects a breakdown in the normal integration of sensory information and cognitive processes (Willner, 1984; Revonsuo et al., 2009).

The primary visual cortex and associative visual areas are heavily implicated in the visual phenomena produced by hallucinogens (Cole & Katz, 1964). Simple hallucinations, such as geometric patterns or flashes of light, may originate from abnormal activation in early visual pathways, while complex hallucinations of objects, people, or scenes likely involve higher-order visual association cortices in the temporal and parietal lobes (Schildkrout, 2014; Manford, 1998). Lesions in these areas can produce similar phenomena, such as in the Charles Bonnet syndrome, where visually impaired individuals experience complex visual hallucinations (Teunisse, 2002; Manford, 1998).

The limbic system, including the hippocampus, amygdala, and anterior cingulate gyrus, is crucial for emotional processing and memory. The intense and labile emotional experiences during intoxication, from euphoria to terror, are thought to result from drug-induced modulation of these structures (Cole & Katz, 1964; Willner, 1984). PET studies in related conditions like schizophrenia have implicated limbic areas in the generation of psychotic symptoms (Dodd, 2007). The hippocampus, in particular, is a key site for neurogenesis and plasticity and is vulnerable to the effects of drugs of abuse, which may contribute to long-term cognitive and emotional sequelae (Dodd, 2007; Hyytiä, 2015).

The prefrontal cortex (PFC) is the seat of executive functions, including planning, judgment, and self-monitoring. Functional neuroimaging studies in schizophrenia consistently show hypofrontality, or reduced PFC activity, which is associated with negative symptoms and cognitive deficits (Dodd, 2007). The disorganized thought, impaired judgment, and loss of insight seen during hallucinogen intoxication suggest a transient disruption of PFC function (Iversen et al., 2009). The experience of "ego dissolution" or the breakdown of the sense of self, a hallmark of the psychedelic experience, likely involves a disruption of the default mode network (DMN), a network of brain regions including the medial PFC and posterior cingulate cortex that is active during self-referential thought (Wasti, 2025). Psychedelics are thought to destabilize this network, increasing connectivity between brain networks that are normally segregated (Wasti, 2025).

The thalamus acts as a crucial sensory relay station, gating the flow of information to the cortex. Hallucinogens may disrupt this filtering mechanism, leading to a state of sensory overload and contributing to perceptual distortions and synesthesia (Willner, 1984). Pathological changes in the thalamus have been observed in schizophrenia and are hypothesized to contribute to psychotic symptoms (Dodd, 2007). Similarly, brainstem structures, including the locus coeruleus (norepinephrine) and raphe nuclei (serotonin), are primary targets for many hallucinogens and are responsible for regulating arousal, sleep-wake cycles, and mood (Manford, 1998). Disruption of these systems can lead to altered states of arousal, sleep disturbances, and the intrusion of dream-like states into wakefulness, a phenomenon seen in both hallucinogen intoxication and sleep disorders like narcolepsy (Manford, 1998; Mignot, 2011).

## Genetic and Molecular Basis

The response to hallucinogenic drugs exhibits significant inter-individual variability, suggesting a substantial contribution of genetic factors to both the acute intoxication experience and the risk for long-term adverse outcomes (Cole & Katz, 1964). While the specific genetic architecture of hallucinogen intoxication is largely unexplored in the provided literature, principles from related fields of psychopharmacology and psychiatric genetics offer a framework for understanding this heterogeneity. Heritability, candidate genes, and molecular pathways are all likely to play a role in modulating an individual's susceptibility and response.

### Genetic Factors and Heritability

Genetic predisposition is a known factor in a range of related conditions, from substance use disorders to primary psychotic illnesses (Dodd, 2007; Blum & Trachtenberg, 1988). For instance, twin studies in schizophrenia have demonstrated a heritability of nearly 50% for monozygotic twins, indicating a strong genetic component (Dodd, 2007). While hallucinogens do not typically produce dependence in the same manner as opioids or alcohol (Iversen et al., 2009), the propensity to use these substances and the nature of the psychological experience may be heritable. Furthermore, the risk of developing a persistent, drug-induced psychosis following hallucinogen use may be significantly elevated in individuals with a family history of schizophrenia or other psychotic disorders, suggesting a shared genetic vulnerability (Dodd, 2007; Mauri, 2016). Some individuals appear to have a genetic predisposition to disorders like hypersomnia, which can be induced or mimicked by certain substances (Unknown, 2019). The link between hallucinogen use and the unmasking of a latent psychosis suggests that these drugs can act as environmental stressors that trigger a genetically vulnerable phenotype (Sommer & Arango, 2017; Yui et al., 2006).

A critical area of genetic influence lies in pharmacokinetics—how the body metabolizes drugs. Individual differences in the activity of cytochrome P450 (CYP450) enzymes, which are responsible for metabolizing a wide range of psychotropic substances, can lead to significant variations in drug plasma levels and duration of action (Petit & Sansone, 2011). For example, genetic polymorphism in the CYP2D6 isoenzyme can result in ultrarapid, extensive, intermediate, or poor metabolizer phenotypes (Petit & Sansone, 2011). An individual who is a poor metabolizer of a particular hallucinogen would experience higher plasma concentrations for a longer duration from a standard dose, increasing the risk of toxicity and severe adverse reactions. Conversely, an ultrarapid metabolizer might experience a blunted or shorter-lived effect. Such genetic variability in drug metabolism could partly explain why some individuals experience profound and distressing effects while others have milder experiences with the same dose of a substance (Petit & Sansone, 2011).

### Candidate Genes and Molecular Mechanisms

While specific genes for hallucinogen response are not detailed in the provided literature, candidate genes can be inferred from the drugs' mechanisms of action.

**Serotonin System Genes:** Given the primary role of the 5-HT2A receptor in mediating the effects of classic hallucinogens, genes encoding for this receptor (e.g., HTR2A) are strong candidates for influencing individual responses (Jalal, 2018). Polymorphisms in HTR2A could alter receptor density, affinity for ligands, or downstream signaling efficiency, thereby modulating the intensity of the psychedelic experience (Jalal, 2018). Similarly, genes related to the serotonin transporter (SERT), which is the target of many antidepressants and also involved in the action of drugs like MDMA, could influence susceptibility to serotonergic toxicity (Meneses, 2013; López‐Arnau et al., 2022).

**Dopamine System Genes:** Genes involved in the dopamine system are relevant to the psychotic symptoms that can arise during intoxication. For example, variations in the gene for the dopamine D2 receptor (DRD2) have been linked to vulnerability to flashbacks from methamphetamine psychosis, a condition with phenomenological overlap with hallucinogen-induced psychosis (Yui et al., 2006). Alterations in dopamine transporter (DAT) genes or genes for enzymes that metabolize dopamine, such as catechol-O-methyltransferase (COMT), are implicated in schizophrenia and could likewise modulate the risk and severity of drug-induced psychosis (Dodd, 2007; Lenzenweger, 2018).

**Glutamate and GABA System Genes:** For dissociative hallucinogens like PCP and ketamine, genes related to the NMDA receptor subunits are plausible candidates. For GABAergic hallucinogens, genes encoding subunits of the GABAA receptor complex could play a similar role (Hollister, 1990).

Beyond receptor genes, molecular pathways involved in neuroplasticity and cellular stress responses are also relevant. Psychostimulants and hallucinogens can induce the expression of immediate early genes, which are involved in long-lasting neuroadaptive changes (Yui et al., 2006). These molecular adaptations may underlie the development of behavioral sensitization, where repeated drug exposure leads to an augmented response, and could be a mechanism for the persistence of symptoms or the development of flashbacks (Yui et al., 2006; Brodrick & Mitchell, 2015). The process of "kindling," a phenomenon where repeated sub-threshold stimuli can lead to a full-blown response, has been proposed as a model for both epilepsy and certain drug-induced behavioral syndromes, suggesting a role for long-term potentiation and synaptic plasticity (Pontius, 1990).

## Brain Structure and Function

Hallucinogen intoxication induces a transient but profound alteration in brain function, manifesting as the characteristic changes in perception, cognition, and emotion. While acute intoxication is primarily a functional state, chronic use or severe toxic reactions can be associated with more lasting structural and functional changes. Evidence from neuroimaging and neuropathological studies, often drawn from analogous conditions like primary psychoses and other substance use disorders, provides critical insights into the neural substrates affected.

### Neuroimaging Findings

Neuroimaging techniques offer a non-invasive window into the brain's structure and function, allowing researchers to investigate the effects of hallucinogens.

**Functional Neuroimaging:** Functional studies focus on brain activity during intoxication or in chronic users. Electroencephalography (EEG) has long been used to measure the brain's electrical activity. Early studies with LSD noted changes in brain electrical patterns, such as an increase in alpha rhythm synchrony, reflecting altered states of consciousness (Rinkel et al., 1952; Glueck, 2017). EEG is also critical in the differential diagnosis of altered mental states, helping to distinguish intoxication-induced psychosis or delirium from nonconvulsive status epilepticus, which can present with similar symptoms of confusion and behavioral change (Kaplan, 2003; Mani, 2022).

More advanced techniques like Positron Emission Tomography (PET) allow for the in-vivo measurement of neurochemical processes, such as receptor occupancy. PET studies have been instrumental in understanding the mechanism of antipsychotic drugs, demonstrating that typical antipsychotics achieve high D2 receptor occupancy, while atypical agents show a more complex profile with lower D2 and significant D1 and other receptor binding (Dodd, 2007; Volkow & Wolf, 1991). Such techniques hold promise for directly visualizing how hallucinogens bind to and activate their target receptors, like the 5-HT2A receptor, in the human brain, and for quantifying the downstream effects on dopamine and other neurotransmitter systems (Volkow & Wolf, 1991). Functional imaging studies in schizophrenia have also identified patterns of "hypofrontality" (reduced frontal lobe activity) associated with negative and cognitive symptoms, providing a model for the transient executive dysfunction seen during intoxication (Dodd, 2007).

**Structural Neuroimaging:** Structural imaging, such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), assesses the brain's anatomy. While a single episode of hallucinogen intoxication is not expected to cause gross structural changes, these techniques are crucial for ruling out other causes of acute psychosis or altered mental status, such as stroke, intracranial hemorrhage, tumors, or encephalitis (Griswold et al., 2015; Kokurcan & Atbaşoğlu, 2015). In cases of severe intoxication leading to complications like hyperthermia, seizures, or severe hypertension, neuroimaging may reveal evidence of secondary brain injury, such as cerebral edema or ischemic lesions (Chang et al., 2025; Prajapati et al., 2024).

Chronic, heavy use of some substances has been associated with structural brain changes. For example, long-term alcohol abuse can lead to cerebral atrophy (Farre Albaladejo, 1989). Diffusion Tensor Imaging (DTI), a sensitive MRI technique, can characterize the microstructure of white matter tracts, providing a measure of brain connectivity. DTI studies have demonstrated an impact of chronic cannabis use on the developing adolescent brain, suggesting that substance use during this critical period can alter neural wiring (Anghelescu et al., 2018). It is plausible that chronic use of other hallucinogens could produce similar microstructural changes, contributing to long-term cognitive or psychiatric sequelae. Furthermore, some of the most consistent neuroanatomical findings in chronic schizophrenia include ventricular enlargement and reductions in the volume of the frontal lobe, temporal lobe, hippocampus, and thalamus (Dodd, 2007). These findings provide a template for investigating potential long-term structural consequences in individuals who develop a persistent psychosis following hallucinogen use.

### Neuroanatomical Correlates

The diverse symptoms of hallucinogen intoxication can be mapped onto the functions of specific brain structures and networks.

**Perceptual Disturbances:** Visual hallucinations are a cardinal feature of intoxication with serotonergic hallucinogens (Cole & Katz, 1964). These experiences likely arise from aberrant activity in the visual cortex and its connections. The occipital lobe is the primary processing center for vision, but higher-order association areas in the temporal and parietal lobes are necessary for interpreting visual information and forming complex perceptions (Manford, 1998). Disruption of these areas can lead to visual illusions (misinterpretations of real stimuli) and hallucinations (perceptions without stimuli) (Borruat, 1999; Schildkrout, 2014). Auditory hallucinations are less common with classic hallucinogens but can be a feature of toxic psychoses (Ali et al., 2011). These are thought to involve auditory processing areas in the temporal lobe (Sommer et al., 2012). Olfactory and gustatory hallucinations are often linked to dysfunction in the temporal lobes (Schildkrout, 2014). Tactile hallucinations, such as formication (the sensation of insects crawling on the skin), can occur with stimulant-like hallucinogens and may be related to abnormal processing in the somatosensory cortex (Lepping et al., 2015).

**Cognitive and Emotional Dysregulation:** The profound alterations in thought, mood, and sense of self point to dysfunction in higher-order association cortices and the limbic system. The prefrontal cortex, responsible for executive functions, is likely impaired, leading to disorganized thought, poor judgment, and loss of insight (Iversen et al., 2009). The experience of ego dissolution suggests a functional decoupling of the Default Mode Network (Wasti, 2025). The intense emotional lability, ranging from ecstasy to terror, reflects the powerful modulation of limbic structures like the amygdala and anterior cingulate cortex (Willner, 1984; Saver & Rabin, 1997). Memory impairment, a feature of many intoxication states, implicates the hippocampus and medial temporal lobe structures (Adair & Barrett, 2003; Dodd, 2007).

**Delirium and Altered Consciousness:** Intoxication with some hallucinogens, particularly anticholinergics, results in delirium—an acute confusional state characterized by fluctuating levels of consciousness and attention (Schildkrout, 2014; Sprigings, 2018). This global brain dysfunction is thought to involve widespread disruption of cortical and subcortical networks, particularly those involving acetylcholine that regulate arousal and cognition (Heffernan et al., 2014; Lipowski, 1987). The brainstem reticular activating system, crucial for maintaining wakefulness, is a key site of action for many anesthetic and sedative drugs and is likely modulated during severe intoxication leading to stupor or coma (Horton, 1980; Ciszowski & Mietka-Ciszowska, 2013).

## Developmental Neurobiology

The effects of hallucinogen intoxication are not uniform across the lifespan; the developing brain, particularly during adolescence, exhibits unique vulnerabilities to the neurotoxic and neurobehavioral effects of psychoactive substances (Hyytiä, 2015). This period is characterized by significant neurodevelopmental processes, including synaptic pruning, myelination, and the maturation of key neurotransmitter systems, especially in the prefrontal cortex (Sommer & Arango, 2017). Exposure to hallucinogens during these critical periods can disrupt normal developmental trajectories, potentially leading to long-term psychiatric and cognitive consequences (Hyytiä, 2015; Catheline, 2005).

### Adolescent Vulnerability

Adolescence is a period of heightened risk-taking and experimentation, which includes the use of illicit substances (Mauri, 2016). The age of first use of drugs like cannabis and cocaine has dramatically decreased, increasing the duration of exposure during a vulnerable neurodevelopmental window (Mauri, 2016). The adolescent brain is particularly susceptible to the effects of drugs of abuse (Hyytiä, 2015). The prefrontal cortex, which governs executive functions like impulse control and decision-making, is one of the last brain regions to fully mature, a process that continues into the early twenties (Sommer & Arango, 2017). Psychoactive substances can interfere with this maturation, potentially leading to persistent deficits in these crucial cognitive domains (Hyytiä, 2015).

Neuroimaging studies have begun to objectify the impact of substance use on the adolescent brain. For instance, diffusion tensor imaging (DTI) has revealed alterations in white matter microstructure in adolescents who use cannabis, suggesting that the drug may interfere with the development of neural connectivity (Anghelescu et al., 2018). Chronic substance use during this period has been linked to impairments in attention, memory, and learning (Farre Albaladejo, 1989; Hyytiä, 2015), which can contribute to academic problems and school failure (Catheline, 2005).

Furthermore, the onset of many primary psychotic disorders, most notably schizophrenia, typically occurs during late adolescence or early adulthood (Buckley & Foster, 2014; Sunshine & McClellan, 2023). There is compelling evidence that substance use, particularly cannabis, can act as a precipitating factor, increasing the risk of psychosis in genetically predisposed individuals and potentially worsening the course of the illness (Mauri, 2016; Thomas, 1993; Kristensen, 1994). The use of hallucinogens can trigger a first psychotic episode in vulnerable teenagers, making it difficult to distinguish between a transient, substance-induced psychosis and the onset of a chronic schizophrenic disorder (Mauri, 2016; Sommer & Arango, 2017). This prodromal phase is a critical period for intervention, as a shorter duration of untreated psychosis is associated with better long-term outcomes (Deakin & Lennox, 2013).

### Critical Periods and Neurodevelopmental Disorders

The concept of critical periods in brain development suggests that exposure to certain insults, including drugs, at specific times can have profound and lasting effects. Neurodevelopmental disorders such as autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD) involve alterations in brain wiring and function that begin early in life (Gopalan, 2016; Unknown, 2015). Children and adolescents with these pre-existing conditions may be particularly vulnerable to the adverse effects of hallucinogens. The core symptoms of ADHD, such as inattention and impulsivity, may increase the likelihood of substance experimentation (Vitiello et al., 2006). Conversely, the cognitive and behavioral effects of hallucinogen intoxication can mimic symptoms of ADHD or other neurodevelopmental disorders, complicating diagnosis and management (Vallée & Pandit, 1991).

Early life trauma is another significant factor that can alter neurodevelopmental trajectories and increase vulnerability to both substance use and psychiatric disorders in adolescence and adulthood (Bendall et al., 2011). Traumatic experiences can disrupt the development of stress-response systems, such as the hypothalamic-pituitary-adrenal (HPA) axis, and alter the structure and function of brain regions like the hippocampus and prefrontal cortex (Kazymova et al., 2019). This can create a predisposition to anxiety, depression, and psychosis, which may be unmasked or exacerbated by the use of hallucinogenic drugs (Bendall et al., 2011; Karon, 1990).

### Long-Term Consequences

While the acute intoxication state is transient, the neurobiological changes initiated by hallucinogen use, especially during development, can have long-lasting implications. The brain's neuroadaptive processes, which are attempts to maintain homeostasis in the face of drug-induced changes, can themselves become maladaptive (Willner, 1984; Kreek, 2011). For example, chronic stimulation or blockade of neurotransmitter receptors can lead to changes in receptor density or sensitivity, a process implicated in tolerance and withdrawal syndromes (Hughes et al., 1994). These long-term changes may contribute to the persistence of perceptual disturbances in Hallucinogen Persisting Perception Disorder (HPPD) or the increased susceptibility to stress-induced psychosis in former users (Brodrick & Mitchell, 2015; Orsolini et al., 2016).

The cognitive deficits associated with chronic substance use in adolescence, such as impaired attention and working memory, may persist even after cessation of the drug, potentially representing a permanent alteration of the developmental trajectory (Hyytiä, 2015; Farre Albaladejo, 1989). This underscores the importance of prevention and early intervention efforts targeted at young people to mitigate the potential for hallucinogens to derail the crucial neurodevelopmental processes of childhood and adolescence (Catheline, 2005).

## Treatment Mechanisms

The management of Other Hallucinogen Intoxication is primarily symptomatic and supportive, aimed at ensuring the patient's safety and alleviating distressing symptoms until the drug is metabolized and eliminated (Williams & Erickson, 2000). The biological basis of these interventions lies in counteracting the acute neuropharmacological disruptions caused by the hallucinogenic substance. Treatment strategies often involve a combination of non-pharmacological and pharmacological approaches, targeting the specific neurotransmitter systems implicated in the intoxication syndrome (Marder, 2006).

### Management of Acute Agitation and Psychosis

A common and urgent presentation of hallucinogen intoxication is acute agitation, which can range from mild restlessness and anxiety to severe psychomotor excitement, aggression, and violent behavior (Zareifopoulos & Panayiotakopoulos, 2019; Marder, 2006). This state can pose a significant risk to the patient and others (Jain et al., 2015). The initial management involves creating a calm, quiet, and non-stimulating environment and providing verbal reassurance, a technique often referred to as "talk-down" therapy (Taylor, 1970; Williams & Erickson, 2000). This approach aims to reduce sensory input and anxiety, which can exacerbate the perceptual distortions and paranoia associated with intoxication (Taylor, 1970).

When agitation is severe or does not respond to non-pharmacological measures, pharmacotherapy is indicated (Marder, 2006; Zareifopoulos & Panayiotakopoulos, 2019). Benzodiazepines are often the first-line agents for managing agitation and anxiety from various causes, including substance intoxication (Marder, 2006; Nelson & Chouinard, 1999). These drugs, such as lorazepam or diazepam, act as positive allosteric modulators of the GABAA receptor, enhancing the inhibitory effects of GABA throughout the central nervous system (Willner, 1984; Nelson & Chouinard, 1999). This widespread neuronal inhibition leads to sedation, anxiolysis, and muscle relaxation, effectively counteracting the CNS hyperexcitability that can manifest as agitation and seizures (Weaver, 2015; Williams & Erickson, 2000).

For patients with prominent psychotic symptoms, such as severe paranoia, delusions, or hallucinations, antipsychotic medications may be necessary (Marder, 2006; Janicak, 2014). Both typical (first-generation) and atypical (second-generation) antipsychotics are used. Typical antipsychotics like haloperidol primarily act as antagonists at dopamine D2 receptors, which is consistent with their efficacy in dampening the dopaminergic hyperactivity thought to underlie psychosis (Dodd, 2007; Volkow & Wolf, 1991). Atypical antipsychotics, such as olanzapine or risperidone, have a more complex receptor binding profile, including antagonism at both D2 and serotonin 5-HT2A receptors (Montes & Rey, 2009; Mailman & Murthy, 2010). This dual action may be particularly beneficial for hallucinogen-induced psychosis, given the primary role of 5-HT2A receptor agonism in the action of classic hallucinogens (Latt et al., 2009). The combination of an antipsychotic with a benzodiazepine is a common and effective strategy for rapid tranquilization (Garza-Treviño, 1988; Zareifopoulos & Panayiotakopoulos, 2019). However, caution is required, as some antipsychotics, particularly those with strong anticholinergic properties, can worsen confusion or delirium, especially in cases of intoxication with deliriant substances (Hasan & Mooney, 1979).

### Targeting Specific Hallucinogen Mechanisms

As our understanding of the specific neuropharmacology of different hallucinogens improves, more targeted treatment strategies are being explored. For classic serotonergic hallucinogens like LSD and psilocybin, the primary mechanism is 5-HT2A receptor agonism (Jalal, 2018). This has led to the proposal that selective 5-HT2A receptor inverse agonists, such as pimavanserin, could serve as a specific antidote to reverse the hallucinatory and fear-inducing effects of these drugs (Jalal, 2018). This represents a shift from non-specific sedation to a mechanism-based intervention designed to directly counteract the drug's primary effect at the receptor level.

In cases of intoxication with anticholinergic agents, which cause delirium by blocking muscarinic acetylcholine receptors, the specific antidote is a centrally-acting cholinesterase inhibitor like physostigmine (Schneck & Rupreht, 1989). By inhibiting the enzyme that breaks down acetylcholine, physostigmine increases cholinergic transmission in the brain, thereby reversing the delirium and other central and peripheral symptoms of the intoxication (Cook & Spence, 1997; Hasan & Mooney, 1979).

For severe intoxication with stimulant-like hallucinogens (e.g., MDMA, synthetic cathinones) that can lead to serotonin syndrome, management focuses on discontinuing the offending agent, supportive care to manage hyperthermia and autonomic instability, and in severe cases, administration of a serotonin antagonist like cyproheptadine (Scotton et al., 2019; Yates et al., 2011). Benzodiazepines are also crucial for controlling agitation and neuromuscular hyperactivity in this context (Scotton et al., 2019).

### Management of Complications and Long-Term Sequelae

Hallucinogen intoxication can lead to various medical and neurological complications that require specific biological interventions. Seizures, which can be triggered by stimulants, dissociatives, or severe serotonergic or anticholinergic toxicity, are treated with benzodiazepines and other anticonvulsant drugs (Coleman, 2004; Brust, 2002). Hyperthermia, a potentially fatal complication of stimulant and serotonergic toxicity, requires aggressive cooling measures and supportive care (Schneir & Clark, 2007). Rhabdomyolysis, the breakdown of muscle tissue, can result from intense psychomotor agitation, seizures, or hyperthermia and may lead to acute kidney injury, requiring aggressive fluid resuscitation and sometimes dialysis (Radovanović et al., 2012).

For long-term sequelae like Hallucinogen Persisting Perception Disorder (HPPD), which involves persistent or recurrent perceptual disturbances, the biological basis is poorly understood and there are no established treatments (Brodrick & Mitchell, 2015; Orsolini et al., 2016). Management is often empirical, with reports of some success using benzodiazepines (like clonazepam), anticonvulsants, or atypical antipsychotics, suggesting that ongoing neuronal hyperexcitability or receptor dysregulation may be involved (Orsolini et al., 2016).

## Future Directions

The study of Other Hallucinogen Intoxication, while possessing a long history, remains a field with many unanswered questions and significant opportunities for future research. The re-emergence of scientific interest in psychedelics for therapeutic purposes, coupled with the ongoing public health challenges posed by new psychoactive substances (NPS), has created a pressing need to deepen our biological understanding of these compounds (Riedlinger & Riedlinger, 1994; Martinotti et al., 2024). Future research must focus on elucidating the precise neural mechanisms of intoxication, identifying biomarkers for risk and prognosis, and developing more targeted and effective treatments.

One of the most promising avenues for future research lies in the application of advanced neuroimaging techniques. While early studies utilized EEG to document changes in brain electrical activity during intoxication (Rinkel et al., 1952), modern methods like functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) can provide much greater spatial and neurochemical resolution. Future studies could use fMRI to map the changes in functional connectivity within and between large-scale brain networks, such as the default mode network, during the acute psychedelic state (Wasti, 2025). This would help to objectively characterize the neural correlates of subjective experiences like ego dissolution and altered perception. PET imaging, which has been crucial in mapping the dopamine system in schizophrenia (Volkow & Wolf, 1991), could be employed to directly measure receptor occupancy of hallucinogens at 5-HT2A and other targets in the human brain, and to quantify their downstream effects on dopamine, glutamate, and other neurotransmitter systems in real-time. Such studies could clarify how biochemical changes give rise to altered states of consciousness (Willner, 1984).

The genetic basis of individual differences in response to hallucinogens is another critical area for investigation. While there are few data on the treatment of individuals who use hallucinogens (Rastegar & Fingerhood, 2015), it is clear that responses are highly variable (Cole & Katz, 1964). Future genome-wide association studies (GWAS) could identify genetic variants in neurotransmitter receptor genes (e.g., HTR2A), transporter genes, or metabolic enzyme genes (e.g., CYP450 family) that predispose individuals to more intense subjective effects, adverse reactions like panic or psychosis, or long-term complications such as HPPD (Petit & Sansone, 2011; Jalal, 2018). Identifying these genetic risk factors could eventually allow for personalized risk assessment and might shed light on the shared genetic vulnerabilities between substance-induced psychosis and primary psychotic disorders like schizophrenia (Dodd, 2007).

At the molecular and cellular level, more research is needed to understand the long-term neuroplastic changes induced by hallucinogens. Animal models have shown that psychostimulants can induce lasting changes in gene expression and synaptic structure (Yui et al., 2006), and there is emerging evidence that psychedelics may promote neurogenesis and synaptogenesis (Maćkowiak, 2023). Investigating these processes could explain the mechanisms behind both the potential therapeutic effects of psychedelics and the pathophysiology of persistent adverse effects (Corne & Mongeau, 2019). Understanding these neuroadaptive changes is crucial for developing interventions that could prevent or reverse the long-term consequences of hallucinogen use (Kreek, 2011).

From a therapeutic standpoint, a deeper neurobiological understanding will facilitate the development of novel, mechanism-based treatments. The proposal to use selective 5-HT2A inverse agonists like pimavanserin for serotonergic hallucinogen intoxication is a prime example of this targeted approach (Jalal, 2018). As the specific receptor interactions of various NPS are identified, similar strategies could be developed to create specific antidotes or treatments for their unique toxicities (Martinotti et al., 2024). There is also a need for well-controlled clinical trials to evaluate the efficacy of existing and novel pharmacological agents for managing both acute intoxication and chronic sequelae like HPPD, for which there is currently a lack of evidence-based guidance (Orsolini et al., 2016; Rastegar, 2020).

Finally, the relationship between hallucinogen-induced states and primary psychiatric disorders remains a fertile ground for research (Cole & Katz, 1964). Using hallucinogens as pharmacological probes to induce transient, reversible psychosis-like states in healthy volunteers can provide invaluable insights into the neurobiology of schizophrenia and other psychotic disorders (Hermle et al., 1996; Rinkel et al., 1952). By studying the neural circuit disruptions and neurochemical imbalances in these model psychoses, we may be able to identify novel therapeutic targets for primary psychiatric illnesses (Iversen et al., 2009).

## Conclusion

Other Hallucinogen Intoxication is a multifaceted neuropsychiatric syndrome arising from the complex interaction of diverse chemical compounds with the brain's intricate neurobiological machinery. The clinical presentation, ranging from altered perception and mood to frank psychosis and delirium, is a direct manifestation of drug-induced disruption of key neurotransmitter systems, including the serotonergic, dopaminergic, glutamatergic, and cholinergic pathways (Pechnick et al., 2014; Iversen et al., 2009). The profound subjective effects, such as visual hallucinations, ego dissolution, and emotional lability, reflect functional alterations in large-scale neural circuits connecting cortical, limbic, and subcortical regions (Willner, 1984; Wasti, 2025).

The biological basis of this intoxication is not monolithic. Serotonergic hallucinogens like LSD and psilocybin primarily exert their effects through 5-HT2A receptor agonism, producing the classic psychedelic state (Latt et al., 2009; Jalal, 2018). In contrast, dissociatives like PCP target the NMDA glutamate receptor, leading to a state of disconnection and depersonalization, while deliriants such as atropine produce a toxic confusional state through anticholinergic mechanisms (Hollister, 1990; Schildkrout, 2014). This heterogeneity underscores the importance of a neuropharmacologically informed approach to diagnosis and management.

While acute intoxication is a transient functional state, its biological impact can have lasting consequences. The developing adolescent brain appears particularly vulnerable to disruption by these substances, with potential long-term effects on cognitive function and psychiatric health (Hyytiä, 2015; Anghelescu et al., 2018). Chronic sequelae such as Hallucinogen Persisting Perception Disorder (HPPD) and the potential for hallucinogens to trigger or unmask enduring psychotic illness in susceptible individuals highlight the capacity of these drugs to induce persistent neuroadaptive changes (Brodrick & Mitchell, 2015; Mauri, 2016). Individual genetic factors, particularly those related to drug metabolism and neurotransmitter system function, likely play a crucial role in determining susceptibility to both acute and chronic adverse effects (Petit & Sansone, 2011).

Current treatment approaches are largely supportive and symptomatic, relying on benzodiazepines and antipsychotics to manage agitation and psychosis by modulating GABAergic and dopaminergic systems, respectively (Williams & Erickson, 2000; Marder, 2006). However, an evolving understanding of the specific receptor targets of hallucinogens is paving the way for more precise, mechanism-based interventions (Jalal, 2018). The journey from describing the subjective effects of "psychotomimetic" drugs to mapping their molecular interactions within the brain represents a significant scientific progression (Cole & Katz, 1964; Volkow & Wolf, 1991). Despite these advances, substantial gaps in our knowledge remain, particularly concerning the long-term neurobiological effects and the precise mechanisms underlying the therapeutic potential that is once again being explored (Rastegar & Fingerhood, 2015; Riedlinger & Riedlinger, 1994). Continued research, leveraging advanced neuroimaging, genetic, and molecular tools, is essential to fully unravel the biological basis of hallucinogen intoxication, a phenomenon that continues to challenge and inform our understanding of consciousness, perception, and mental illness.

## References

1. Abad, V. C., & Guilleminault, C. (2004). Emerging drugs for narcolepsy. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.9.2.281
2. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
3. AbdulRahman, I., Yaqoob, Ú., & Bhatti, T. A. (2018). Sleep Disorders Caused by Depression. Clinical Depression. https://doi.org/10.4172/2572-0791.1000131
4. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
5. Abou‐Donia, M. B. (2015). Drugs of Abuse. https://doi.org/10.1002/9781118683484.ch26
6. Abreu, G. D. A., Cláudio, L., Oliveira, L. D., Nogueira, A. D. R., & Bloch, K. V. (2009). Quadro clínico: reconhecimento do paciente com apneia obstrutiva do sono Clinical presentation: recognizing the patient with obstructive sleep apnea.
7. Acquadro, M. A. (1998). Headache and sinusitis. Current Opinion in Otolaryngology & Head & Neck Surgery. https://doi.org/10.1097/00020840-199802000-00001
8. Adair, J. C., & Barrett, A. M. (1993). Anosognosia. https://doi.org/10.1093/oso/9780195081237.003.0009
9. Adair, J. C., Schwartz, R. L., & Barrett, A. M. (2003). Anosognosia. https://doi.org/10.1093/oso/9780195133677.003.0010
10. Adams, A. C. (2018). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190206895.003.0012
11. Albaladejo, F. (1989). [Neurologic complications of drug addiction. General aspects. Complications caused by cannabis, designer drugs and volatile substances].. PubMed.
12. Albalawi, R., Alsahli, H., Almutairi, N. B., & Alhashemi, M. (2024). Acute psychosis and behavioural changes with seizure-like hyperactive psychomotor activity secondary to isotretinoin initiation in a healthy young male: case report. Annals of Medicine and Surgery. https://doi.org/10.1097/ms9.0000000000001726
13. Ali, A. P. D. W. D. A. (2024). NEUROPHYSIOLOGY OF SLEEP PARALYSIS. International Journal of Education and Social Science Research. https://doi.org/10.37500/ijessr.2024.7106
14. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
15. Ali, S., Patel, M., Avenido, J., Bailey, R. K., Jabeen, S., & Riley, W. J. (2011). Hallucinations: Common Features and Causes: Awareness of Manifestations, Nonpsychiatric Etiologies Can Help Pinpoint a Diagnosis. Current psychiatry.
16. Alt, M. (2011). Lethargie bei Hungernden; Überlebensstrategie oder klinische Depression? Kognitive und psychovegetative Depressionssymptome im Hungerstoffwechsel unter besonderer Berücksichtigung der Anorexia Nervosa.
17. Ananto, A. S., & Suryati, E. (2019). Ensefalopati Hipertensi pada Anak dengan Glomerulonefritis Akut Pasca Streptokokal.
18. Anderson, T., Heitger, M., & Macleod, A. D. (2006). Concussion and mild head injury. Practical Neurology. https://doi.org/10.1136/jnnp.2006.106583
19. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
20. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). ORAL PRESENTATION – ABSTRACTS. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s.1
21. Antelo, M. J. G., Santos, H., Barbeito, Y. I., Silva, J. J. D., & Sobrido, M. J. (2012). Tratamiento de los trastornos de la marcha en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012532
22. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
23. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 1). Current psychiatry. https://doi.org/10.12788/cp.0242
24. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 2). Current psychiatry. https://doi.org/10.12788/cp.0253
25. Ariff, K. M., & Hassan, Z. A. (2006). Insomnia: Case Studies In Family Practice.. DOAJ (DOAJ: Directory of Open Access Journals).
26. Arnáez, S. (2019). Vulnerabilidad cognitiva a la hipocondría: intrusiones, valoraciones y creencias disfuncionales/ cognitive vulnerability to hypochondriasis: intrusions, appraisals and dysfunctional beliefs.
27. Asadi, S. (2023). The Role of Bio- Psychological Factors in Sleep Anxiety and Hypomania Disorder. https://doi.org/10.31579/2835-2882/016
28. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
29. Aydinak, S., Yalçın, C. Ö., & Abudayyak, M. (2018). Psychiatric Adverse Effects of Non-steroidal Analgesic Anti-inflammatory Drugs. Journal of Literature Pharmacy Sciences. https://doi.org/10.5336/pharmsci.2017-58076
30. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
31. b'Volkow, N. D., & b'Wolf, A. P. (1991). b'THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.'.
32. Bach, S. (2018). States of consciousness. Routledge eBooks. https://doi.org/10.4324/9780429471391-3
33. Balmer, H. C. (2014). Notfälle bei Demenz – was Sie tun können. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a000634
34. Baran, A. S. (2003). Sleep Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.028
35. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
36. Barbosa, T. A., Machado, R. R., Moeda, A. S. G., Gloria, I. R., Shidiq, S., & Brandão, P. (2023). Importância da hidrocefalia como diagnóstico diferencial de síndromes demenciais. Congresso Médico Acadêmico UniFOA.. https://doi.org/10.47385/cmedunifoa.315.5.2018
37. Barker, R. A., & Redfern, C. (2019). Parkinson’s Disease, Religious Belief and Spirituality. Cambridge University Press eBooks. https://doi.org/10.1017/9781316014165.011
38. Barnhill, J. W. (2014). DSM-5TM clinical cases. American Psychiatric Publishing eBooks.
39. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
40. Barrera, M. N. (1999). Mioclonías y Epilepsias Mioclónicas en la infancia. Revista de Neurología. https://doi.org/10.33588/rn.2803.98387
41. Barrio, A. G. D. (2018). Intervención Psicoterapéutica Integrada y Transdiagnóstica en los Trastornos de la Conducta Alimentaria. Revista de Psicoterapia. https://doi.org/10.33898/rdp.v29i110.248
42. Barré, M. (2013). Influence de la cognition sociale (Théorie de l'Esprit) sur la rémission fonctionnelle de la dépression et l'aptitude professionnelle.
43. Barteček, R., Kašpárek, T., & Češková, E. (2011). Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia. Open Medicine. https://doi.org/10.2478/s11536-011-0055-8
44. Bassetti, ■., Bischof, M., Valko, P. O., & Bassetti, C. L. (2005). Dreaming: a neurological view. Schweizer Archiv für Neurologie und Psychiatrie. https://doi.org/10.4414/sanp.2005.01658
45. Basuta, K., Schneider, A., Gane, L. W., Polussa, J., Woodruff, B. K., Pretto, D., Hagerman, R. J., & Tassone, F. (2015). High functioning male with fragile X syndrome and fragile X‐associated tremor/ataxia syndrome. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.37125
46. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
47. Becker, M. A., Weinberger, T. E., & Ocker, L. J. (2022). Mood Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003099062-21
48. Beed, M., Sherman, R. A., & Mahajan, R. (2013). Neurology. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696277.003.0005
49. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
50. Begum, N., Begum, T., & Khatoon, S. (2012). Seizures in Newborn: An Update. Journal of Shaheed Suhrawardy Medical College. https://doi.org/10.3329/jssmc.v4i1.12000
51. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
52. Bendall, S., Jackson, H. J., Hulbert, C., & McGorry, P. D. (2011). Childhood trauma and psychosis: An overview of the evidence and directions for clinical interventions. Family matters.
53. Berg, A. T. (2011). Epilepsy, cognition, and behavior: The clinical picture. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02905.x
54. Berliana, M. C., Razzaq, A., & Jannati, Z. (2023). Penerapan Konseling Individu Dengan Teknik Cognitive Restructuring Untuk Mengatasi Post Traumatic Stress Disorder. Journal of Society Counseling.. https://doi.org/10.59388/josc.v1i2.239
55. Bermúdez, C. M., & Barrientos, M. P. S. (2011). Manejo Integral de un paciente con secuelas neuropsiquiátricas por consumo crónico de alcohol. REVISTA MÉDICAS UIS.
56. Bernal, F. M. (2016). Trastorno delirante: estudio descriptivo de un registro de casos.
57. Bernardo, A. P. M. (2003). O delírio em cuidados paliativos. Revista Portuguesa de Medicina Geral e Familiar. https://doi.org/10.32385/rpmgf.v19i1.9904
58. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
59. Birnbacher, D. (2007). Terminal sedation, euthanasia, and causal roles.. PubMed.
60. Bischoff, P., & Rundshagen, I. (2011). Awareness Under General Anesthesia. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0001
61. Biyani, G., Vandana, S., & Bhatia, P. (2015). Opioids induced serotonin toxicity? Think again. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.160979
62. Black, D. W., & Grant, J. E. (2014). DSM-5TM guidebook : the essential companion to the Diagnostic and statistical manual of mental disorders, fifth edition. American Psychiatric Publishing eBooks.
63. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
64. Boer, M., Udangiu, L. N., & Ţilea, L. (2013). Considerations On The Effectiveness Of Valdoxan Therapy In Depressive And Anxiety Disorders. Management in Health. https://doi.org/10.5233/mih.v17i4.293
65. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
66. Bonevski, D., & Naumovska, A. (2018). Trauma and Anxiety Disorders throughout lifespan: Fear and anxiety from normality to disorder.. PubMed.
67. Bonnet, M. H., & Arand, D. L. (2013). Insomnia. https://doi.org/10.3920/9789086867639_003
68. Borchers, A., & Cagle, L. A. (2018). Look‐Alike Causes of Respiratory Distress. https://doi.org/10.1002/9781119028994.ch50
69. Borchert, A., Möddel, G., & Schilling, M. (2009). Teaching Video Neuro <i>Images</i> : Paroxysmal kinesigenic dyskinesia. Neurology. https://doi.org/10.1212/wnl.0b013e3181a92b66
70. Borelli, C. M., & Solari, H. (2019). Schizophrenia. JAMA. https://doi.org/10.1001/jama.2019.11073
71. Borruat, F. (1999). Hallucinations et illusions visuelles, des symptomes souvent méconnus du praticien. Klinische Monatsblätter für Augenheilkunde. https://doi.org/10.1055/s-2008-1034805
72. Bourin, M., David, D. J., & Dhonnchadha, B. À. N. (2002). Sedation: a non-specific phenomenon -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
73. Bransfield, R. C., & Friedman, K. J. (2019). Differentiating Psychosomatic, Somatopsychic, Multisystem Illnesses and Medical Uncertainty. Healthcare. https://doi.org/10.3390/healthcare7040114
74. Brignole, M. (2006). Neurally mediated syncope. CRC Press eBooks. https://doi.org/10.1201/b13301-22
75. Brodrick, J. E., & Mitchell, B. G. (2015). Hallucinogen Persisting Perception Disorder and Risk of Suicide. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014566314
76. Bronstein, A. M., & Lempert, T. (2010). Management of the patient with chronic dizziness. Restorative Neurology and Neuroscience. https://doi.org/10.3233/rnn-2010-0530
77. Brown, T. A., & Barlow, D. H. (1996). Casebook in Abnormal Psychology.
78. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
79. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
80. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
81. Burk, A., Merchant, A., Rahman, H., Patel, A., Deshmukh, I., Merchant, R., Yam, A. A., Yu, A., Cai, C., Hassam, A., Le, D., & Lambroussis, C. G. (2025). Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. Cureus. https://doi.org/10.7759/cureus.86587
82. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
83. Burn, D. J. (2013). Approach to History Taking and Examination of the Movement Disorder Patient. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199609536.003.0002
84. Bush, S. H., & Gratton, V. (2018). Delirium. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190633066.003.0011
85. Calingasan, N. Y., Sheu, K. R., Baker, H., Gandy, S., & Gibson, G. E. (1996). Thiamine Deficiency as a Model of Selective Neurodegeneration with Chronic Oxidative Deficits. Neurodegenerative Diseases. https://doi.org/10.1007/978-1-4899-0209-2_25
86. Cano‐Vindel, A., Miguel-Tobal, J. J., González, H. M., & Díez, I. I. (1994). El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología.
87. Caplan, L. R., & Aggarwal, A. (2022). Stroke-Related Terms. Cambridge University Press eBooks. https://doi.org/10.1017/9781009030854.044
88. Caraceni, A., Bosisio, M., & Ingham, J. (2003). Confusion and Delirium. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-317-0_5
89. Caradoc-Davies, G. (1988). Feigned Alcohol Abuse. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.152.3.418
90. Cardaci, V., Carminati, M., Tondello, M., Pecorino, B., Serretti, A., & Zanardi, R. (2024). Understanding and treating postpartum depression: a narrative review. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000560
91. Catalano, A., Campanini, T., Risio, C. D., & Mardighian, G. (1970). Vanilmandelicaciduria in the Different Clinical Phases of Manic Depressive Psychosis. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.116.533.435
92. Catheline, N. (2005). [Academic problems and school failure in adolescence].. PubMed.
93. Chakrabarty, A., & Reddy, M. S. (2011). Visual Hallucinations in Mania. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.85399
94. Chang, A. N., Kiyokawa, M., & Grysman, N. (2025). Cocaine Induced Postictal Psychosis: a Rare Cause of Antipsychotic Resistant Psychosis. Hawai‘i Journal of Health &amp Social Welfare. https://doi.org/10.62547/nmiq4624
95. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
96. Charante, E. P. M. V., Richard, E., & Perry, M. (2022). [Forgetfulness].. PubMed.
97. Charles, A. (2012). Migraine is not primarily a vascular disorder. Cephalalgia. https://doi.org/10.1177/0333102412441717
98. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
99. Chauhan, R., Bhunal, S., Gupta, D., Kumar, R., & Sharma, T. (2020). TO STUDY CLINICAL PROFILE OF ACUTE CONFUSIONAL STATE IN A TERTIARY CARE HOSPITAL IN A HILLY AREA.. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/0915904
100. Choi, S. J. (2007). Sleep Breathing Disorder. Tuberculosis & respiratory diseases. https://doi.org/10.4046/trd.2007.63.1.5
101. Choi, W., & Young, M. J. (2023). Disambiguating Consciousness in Clinical Settings. Neurology. https://doi.org/10.1212/wnl.0000000000207765
102. Choi, W.-J., Jeong, M.-S., Lee, S.-G., & Kim, H.-D. (2009). A Case Report of Sleepwalking Disorder with Hypnotherapy. The Korean Society of Oriental Neuropsychiatry.
103. Choo, K.-Q., Wl, L., How, C., & Ng, B. (2015). Hoarding in Singapore. Singapore Medical Journal. https://doi.org/10.11622/smedj.2015131
104. Chouinard, G., & Chouinard, V. (2015). New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000371865
105. Chung, S., Oh, K., Cho, K., & Hwang, I.-K. (2003). Antidepressant-Induced Somnambulism：A Case of Mirtazapine. Sleep Medicine and Psychophysiology.
106. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
107. Cibula, J. E., Eisenschenk, S., Gold, M., Eskin, T. A., Gilmore, R. L., & Heilman, K. M. (2002). Progressive Dementia and Hypersomnolence With Dream-Enacting Behavior. Archives of Neurology. https://doi.org/10.1001/archneur.59.4.630
108. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Rare consciousness disturbances in toxicological practice: akinetic mutism, somnambulism, locked-in syndrome, and psychogenic coma].. PubMed.
109. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
110. Clark, M., & McKinlay, J. (2009). Coma, Confusion, and Agitation in Intensive Care. Competency-based critical care. https://doi.org/10.1007/978-1-84882-070-8_11
111. Coelho, F. M. S. (2014). Narcolepsy – Between the dream and reality. Sleep Science. https://doi.org/10.1016/j.slsci.2014.07.019
112. Coelho, L. R. P., Batista, L. R., Silva, A. C. B., Ramos, A. C. R., Fagundes, L. M., Barros, B. E., Belfort, R. L. D. A., Vieira, M. R. V., Cavalcanti, A. T. L., & Silva, R. R. C. (2024). Diferenciação diagnóstica de crises neurológicas: Epilepsia, Síncope, Crises Psicogênicas, Enxaqueca e Narcolepsia. Europub Journal of Health Research. https://doi.org/10.54747/ejhrv8n2-008
113. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
114. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
115. Coleman, J. J. (2004). Drug-induced seizures. Adverse Drug Reaction Bulletin. https://doi.org/10.1097/00012995-200408000-00001
116. Coliță, C.-I., Hermann, D. M., Fîlfan, M., Coliță, D., Doepnner, T. R., Tica, O. S., Glăvan, D., & Popa‐Wagner, A. (2024). Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy. Clocks & Sleep. https://doi.org/10.3390/clockssleep6040043
117. Collin, A., Reynaert, C., Janne, P., Vause, M., & Cassiers, L. (1989). [Hypochondriasis. Symptom at the crossroad or a road crossing the syndromes?].. PubMed.
118. Colombier, B., Moulias, S., Curatolo, N., Cudennec, T., Müller, F., Preulier, D., & Teillet, L. (2015). Representation and practice about «chimical restraints»: qualitative study with 50 health worker. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2015.0521
119. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
120. Connell, J., Oldham, M., Pandharipande, P. P., Dittus, R. S., Wilson, A. M., Mart, M. F., Heckers, S., Ely, E. W., & Wilson, J. E. (2022). Malignant Catatonia: A Review for the Intensivist. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666221114303
121. Cook, B. A., & Spence, A. (1997). Post-operative central anticholinergic syndrome. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199701000-00001
122. Corne, R., & Mongeau, R. (2019). Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines. Biologie Aujourd hui. https://doi.org/10.1051/jbio/2019015
123. Costa, L. A. P. D., Costa, J. M. D., Silva, L. F. M. D., Raymundi, A. C., Fernandes, B., Resende, L. S. R. E., Silva, C. P., Paula, P. A. F. D., França, A. B. C., Sousa, L. F., & Sousa, A. B. F. (2025). PARTICULARIDADES DA SÍNDROME DE HORNER EM CÃES E GATOS: REVISÃO DE LITERATURA. Aracê.. https://doi.org/10.56238/arev7n4-131
124. Costentin, J. (2015). La dopamine dans tous ses états.
125. Cottencin, O., Danel, T., Goudemand, M., Thomas, P., & Consoli, S. M. (2009). Catatonia recognition and treatment.. PubMed.
126. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
127. Cruz, V. E. R., Palacios, L. P. T., Adriano, M. P. C., Lozada, E. M. V., Quingatuña, D. E. E., Reyes, E. P. B., Sailema, P. I. Y., Inca, J. I. S., & Ruiz, G. B. F. (2020). Avances en el manejo del delirium en los pacientes geriátricos. AVFT – Archivos Venezolanos de Farmacología y Terapéutica. https://doi.org/10.5281/zenodo.4058882
128. Cunha, M. D. A., Vale, L., & Gomides, A. P. M. (2024). Transtornos neurológicos pós-COVID-19. Revista Eletrônica Acervo Saúde. https://doi.org/10.25248/reas.e16896.2024
129. Czajkowska‐Malinowska, M., & Cofta, S. (2014). Obturacyjny bezdech senny i jego społeczne następstwa.
130. Dalamagka, M. I. (2024). Antipsychotics and anesthetic drugs. Magna Scientia Advanced Research and Reviews. https://doi.org/10.30574/msarr.2024.12.1.0141
131. Dalamagka, M. I. (2024). Emergence Delirium in children. International Journal of Science and Research Archive. https://doi.org/10.30574/ijsra.2024.12.2.1408
132. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
133. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
134. Darwish, H. (1980). Promethazine-Induced Acute Dystonic Reactions. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1980.02130220066020
135. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
136. Deakin, J., & Lennox, B. (2013). Psychotic symptoms in young people warrant urgent referral.. PubMed.
137. Delcea, C. (2019). Sexual deviances. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.119
138. Deses, C. D. D. L. (2018). Alteraciones del sueño en personas adultas mayores. Revista de la Facultad de Medicina (México).
139. Desseilles, M., Sterpenich, V., Dang‐Vu, T. T., & Schwartz, S. (2011). REM sleep and emotion regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511921179.044
140. Dewailly, D., & Néraud, B. (2007). Drug-Induced Hyperandrogenism. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-179-6_10
141. Dhar, N., Shree, R., Radhakrishnan, D. M., & Kumar, N. (2020). Hearing Loss in Migraine: An Uncommon Manifestation of a Common Disorder. Journal of Neurosciences in Rural Practice. https://doi.org/10.1055/s-0040-1713337
142. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
143. Dobkin, P. L. (2015). Whole Person Care: More Than Just A New Name. International Journal of Whole Person Care. https://doi.org/10.26443/ijwpc.v3i1.109
144. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
145. Dreyer-Oren, S. E., Mitnaul, L., & Holtzheimer, P. E. (2018). Mood Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy25
146. Drăgoi, A. M., Enache, A., & Trifu, S. (2019). Obsessive-Compulsive Particularities Before And After Remission Of Acute Phase Episodes Of Schizophrenia. The European Proceedings of Social & Behavioural Sciences. https://doi.org/10.15405/epsbs.2019.11.86
147. Duan, J., Huang, W., Zhou, M., Li, X., & Cai, W. (2013). Case report of adjunctive use of olanzapine with an antidepressant to treat sleep paralysis.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2013.05.010
148. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
149. Dugan, P., Holmes, M., & Carlson, C. (2025). Psychosis and Seizures. Epilepsy. https://doi.org/10.1093/med/9780197673751.003.0028
150. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
151. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
152. Dumitrache, M., Anițescu, M., & Cioboat, M. (2024). HEADACHE. International Journal of Family Medicine & Healthcare. https://doi.org/10.33425/2833-0382.1024
153. Díaz, B. C., & Hernández, M. Á. T. (2006). Complicaciones neurológicas por cocaína. Adicciones.
154. Dünser, M. W., & Hasibeder, W. (2009). Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress. Journal of Intensive Care Medicine. https://doi.org/10.1177/0885066609340519
155. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
156. Egger, C., Muehlbacher, M., Nickel, M., Geretsegger, C., & Stuppaeck, C. (2006). A review on hyponatremia associated with SSRIs, reboxetine and venlafaxine. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500500410216
157. Elkan, E.-M., Papuc, A.-M., Goroftei, R. E. B., Banu, E. A., Zlati, M. L., Albeanu, A. G., & Pleșea-Condratovici, A. (2023). DREAMING AND PARASOMNIAS FROM A CEREBRAL STRUCTURAL VIEW. https://doi.org/10.35630/2022/12/psy.ro.6
158. Emilien, G., Dinan, T. G., Lepola, U., & Durlach, C. (2002). Normal and pathological anxiety. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-8157-9_1
159. Emilien, G., Durlach, C., Minaker, K. L., Winblad, B., Gauthier, S., & Maloteaux, J. (2004). Behavioral and psychological impairments. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7842-5_9
160. Eryuda, F., Rokhmani, C. F., & Wahyudho, R. (2019). Skizofrenia Paranoid dengan Riwayat Putus Obat pada Pasien Laki-laki Usia 32 Tahun. Jurnal Medula.
161. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
162. Farne, H., Norris-Cervetto, E., & Warbrick‐Smith, J. (2015). Blackout. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198716228.003.0009
163. Farooq, H., Mohammad, T., Farooq, A., & Mohammad, Q. (2019). Alcohol Withdrawal Mimicking Neuroleptic Malignant Syndrome. Cureus. https://doi.org/10.7759/cureus.4697
164. Farıdhosseını, F., & Zamani, A. (2012). A case report of somnambulism associated with olanzapine.. PubMed.
165. Fasano, A., Lehnerer, S., & Elia, A. E. (2014). Symptoms of dystonia. https://doi.org/10.2217/ebo.13.269
166. Fasmer, O. B., & Øedegaard, K. J. (2002). Are Migraines and Bipolar Disorder Related.
167. Favory, R., Mathieu, D., & Durocher, A. (2011). Vers une diminution des hypnotiques en réanimation. MT. Médecine thérapeutique. https://doi.org/10.1684/met.2011.0315
168. Favrat, B., Guessous, I., Gonthier, A., & Cornuz, J. (2015). [Prolonged or chronic fatigue of unknown origin].. PubMed.
169. Fenichel, G. M. (2022). Altered States of Consciousness. WORLD SCIENTIFIC eBooks. https://doi.org/10.1142/9789811260735_0011
170. Filho, A. C. O., Gomes, L. M. T., Corrêa, A. C., Leão, E. F. D., Cangussu, D. M., & Torres, S. D. A. S. (2019). BRUXISMO DO SONO. Revista Intercâmbio.
171. Fink, M. (2010). Other Uses: Psychosis, Pregnancy, and Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0012
172. Finsterer, J., Keller, H., Reining‐Festa, A., Enzelsberger, B., & Weidinger, F. (2018). Phenytoin‐induced choreoathetosis after serial seizures due to traumatic brain injury and chronic alcoholism. Clinical Case Reports. https://doi.org/10.1002/ccr3.1870
173. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
174. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
175. Forrest, J., Willis, L., Holm, K., Kwon, M. S., Anderson, M. A., & Foreman, M. D. (2007). Recognizing quiet delirium.. PubMed. https://doi.org/10.1097/01.naj.0000265267.77070.0c
176. Fouwels, A., & Timmer, T. J. (2007). [Choking caused by antipsychotics].. PubMed.
177. Francis, M. V. (2016). Migraine without Aura -Towards a New Definition. Journal of Headache & Pain Management. https://doi.org/10.4172/2472-1913.100008
178. Freitas, C., Mendes, A. M., & Queirós, S. (2016). The role of modified states of consciousness in drug use. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1012
179. Frith, C., & Cahill, C. (2019). Psychotic Disorders: Schizophrenia, Affective Psychoses, and Paranoia. Routledge eBooks. https://doi.org/10.4324/9781315542072-15
180. Fronczek, R., Zande, W. L. M. V. D., Dijk, J. G. V., Overeem, S., & Lammers, G. J. (2007). [Narcolepsy: a new perspective on diagnosis and treatment].. PubMed.
181. Fujiki, N., & Nishino, S. (2007). Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152707779940781
182. Fw, K. (1994). [Cannabis and psychoses].. PubMed.
183. García, A. C., Ignacio, Á. S., & Pensado, B. A. (2004). Complicaciones psiquiátricas de la enfermedad de Parkinson: clínica y tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.3907.2004325
184. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
185. García, M. D. S., & Calderón, R. M. (2012). Complicaciones de la estimulación cerebral profunda en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012530
186. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
187. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
188. Garrote, J. B., Casanova, T., Antón, R., Campos, A. R., Pérez, S. C., Sánchez, S. G., Garcia, G., Andrés, L. R., Garcia, M., Canga, C. N., Astorga, A. Á., & Gallego, H. D. L. R. (2016). How strange is everything. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1859
189. Garza-Treviño, E. S. (1988). El manejo de urgencia de los cuadros psicóticos agudos. Salud Mental.
190. Garzoni, L., Vanoni, F., Rizzi, M., Simonetti, G. D., Simonetti, B. G., Ramelli, G. P., & Bianchetti, M. G. (2009). Nervous system dysfunction in Henoch-Schonlein syndrome: systematic review of the literature. Lara D. Veeken. https://doi.org/10.1093/rheumatology/kep282
191. Gauci, S., Hosking, W., & Bruck, D. (2017). Narcolepsy, cataplexy, hypocretin and co-existing other health complaints: A review. Cogent Medicine. https://doi.org/10.1080/2331205x.2017.1312791
192. Gautam, S., Jain, A., Gautam, M., Vahia, V., & Gautam, A. (2017). Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196975
193. Gerlach, M., Mehler‐Wex, C., & Schimmelmann, B. G. (2014). Antipsychotics. https://doi.org/10.1007/978-3-7091-1501-5_5
194. Ghaemi, S. N. (2018). Children. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0028
195. Ghika, J. (2018). [Abnormal movements and internal medicine pathologies].. PubMed.
196. Ghosh, P., & Desousa, A. (2024). Psychedelics: The New Kid on the Block. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_195_23
197. Giannuzzi, R., Testa, A. C., Sollazzo, F., Petrongolo, L., Bernardini, L., & Daini, S. (2013). Psychiatric emergencies (part I): psychiatric disorders causing organic symptoms.. PubMed.
198. Gilchrist, J. M. (1998). Prognosis in Neurology.
199. Glasper, E. A., McEwing, G., & Richardson, J. M. (2011). Chapter 13 Mental health problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199547197.003.0075
200. Gleason, M. M., & Thompson, L. A. (2022). Depression and Anxiety Disorder in Children and Adolescents. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2022.0052
201. Glueck, B. (2017). Psychophysiological Correlates of Meditation: Eeg Changes During Meditation *. Routledge eBooks. https://doi.org/10.4324/9780203785843-56
202. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
203. González, M. J., Bardanca, M. S. G., Vivanco, E. F., Paz, M. T. A., & Allegue, M. D. (2007). Distonía psicógena: un diagnóstico complejo..
204. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
205. Gopalan, R. T. (2016). Intellectual Disability. Advances in psychology, mental health, and behavioral studies (APMHBS) book series. https://doi.org/10.4018/978-1-5225-0089-6.ch001
206. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
207. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
208. Grant, I., Sacktor, N., & McArthur, J. C. (2005). HIV neurocognitive disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0035
209. Graziani, P. (2011). La consommation excessive d’alcool chez la personne âgée. Drogues santé et société. https://doi.org/10.7202/1005300ar
210. Greenfield, M. J., Fobian, A. D., Fargason, R. E., & Birur, B. (2024). Optimizing outcomes when treating functional neurological disorder in acute care settings: case reports depicting the value of diagnostic precision and timely and appropriate psychological interventions using an interdisciplinary framework. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1288828
211. Grigorenko, E. L., Klin, A., & Volkmar, F. R. (2003). Annotation: Hyperlexia: disability or superability?. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/1469-7610.00193
212. Griswold, K., Regno, P. A. D., & Berger, R. C. (2015). Recognition and Differential Diagnosis of Psychosis in Primary Care.. PubMed.
213. Group, M. T., Mackway‐Jones, K., Marsden, J., & Windle, J. (2006). Discriminator Dictionary. https://doi.org/10.1002/9780470757321.oth3
214. Grover, S., Sarkar, S., Jhanda, S., & Chawla, Y. (2014). Psychosis in an adolescent with Wilson′s disease: A case report and review of the literature. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.146530
215. Guerrini, R., & Falchi, M. (2011). Dravet syndrome and <i>SCN1A</i> gene mutation related‐epilepsies: cognitive impairment and its determinants. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.03966.x
216. Gurning, M. R. A. (2023). PENERAPAN ASUHAN KEPERAWATAN JIWA PADA PASIEN SKIZOFRENIA Ny. R DENGAN GANGGUAN PERSEPSI SENSORI: HALUSINASI PENDENGARAN. https://doi.org/10.31219/osf.io/sdjyg
217. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
218. Haddad, P., & Dursun, S. (2007). Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.918
219. Hale, A. S. (1997). ABC of mental health: Anxiety. BMJ. https://doi.org/10.1136/bmj.314.7098.1886
220. Hall, P. A., & Burhan, A. M. (2022). Commentary on Song <i>et al</i>: Brain stimulation for addictions‐ optimizing impact via strategic interleaving with pharmacotherapy, cognitive behavioral therapy, and restructuring the micro‐environment. Addiction. https://doi.org/10.1111/add.15797
221. Hamed, S. A. (2014). Diabetes mellitus and the brain : special emphasis on cognitive function : review. The South African journal of diabetes & vascular disease.
222. Hanel, R. A., Sandmann, M. C., Kranich, M., & Bittencourt, P. R. M. (1998). Síndrome neuroléptica maligna: relato de caso com recorrência associada ao uso de olanzapina. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x1998000500022
223. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
224. Hasan, M., & Mooney, R. (1979). Reversible toxic psychosis.. PubMed.
225. Heffernan, S. P., Oh, E. S., Lyketsos, C. G., & Neufeld, K. J. (2014). Delirium. https://doi.org/10.1002/9781118799574.ch14
226. Hefzi, N., Grekin, J. A., & Ahmed, A. (2019). Mania induced by tramadol-venlafaxine combination. Journal of Opioid Management. https://doi.org/10.5055/jom.2019.0519
227. Heilman, K. M., Watson, R. T., & Valenstein, E. (2003). Neglect and Related Disorders. https://doi.org/10.1093/oso/9780195133677.003.0013
228. Helbig, M., Youssef, N., & Schuetz, S. (2023). 1001 A Case of Unusual Nocturnal Movements Consistent with Paroxysmal Hypnogenic Dyskinesia. SLEEP. https://doi.org/10.1093/sleep/zsad077.1001
229. Hermle, L., Gouzoulis‐Mayfrank, E., & Spitzer, M. (1996). Halluzinogen-induzierte psychische Störungen. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2007-996594
230. Herrlen, S., & Kunze, H. (1979). [EEG changes during clozapin administration compared to other neuroleptic agents. Controlled case study in a particular patient].. PubMed.
231. Heylens, G., Roosens, E., Mulier, J. P., & Fruyt, J. D. (2017). [The use of dexmedetomidine in extreme agitation].. PubMed.
232. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
233. Hj, A., Barrucand, D., & Auzépy, P. (1993). [Alcohol withdrawal syndrome and delirium tremens. Their treatment].. PubMed.
234. Hj, V. V., Maat, A. T., Jm, H., & Am, B. (2006). [Anxiety disorders and epilepsy: not unknown, but sometimes unexpected. A case study].. Tijdschrift voor psychiatrie.
235. Holgate, S. T. (2002). Considerations on third generation antihistamines. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01339.x
236. Hollister, L. E. (1977). Withdrawal From Benzodiazepine Therapy. JAMA. https://doi.org/10.1001/jama.1977.03270410032003
237. Hollister, L. E. (1990). New class of hallucinogens: GABA‐enhancing agents. Drug Development Research. https://doi.org/10.1002/ddr.430210311
238. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
239. Hong, C. (2013). 조현병 스펙트럼 및 기타 정신병적 장애, 성격장애. 한국심리학회 학술대회 자료집.
240. Hong, S. I., Cho, D. H., Kang, H., Chung, D. J., & Chung, M. Y. (2006). Acute Onset of Steroid Psychosis with Very Low Dose of Prednisolone in Sheehan's Syndrome. Endocrine Journal. https://doi.org/10.1507/endocrj.53.255
241. Horton, J. M. (1980). Use of anaesthesia. Care of the unconscious.. BMJ. https://doi.org/10.1136/bmj.281.6232.38
242. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
243. Howland, R. H. (2014). Delirium and Its Prevention with Melatonergic Drugs. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20140423-02
244. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
245. Hughes, J. R., Higgins, S. T., & Bickel, W. K. (1994). Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03744.x
246. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
247. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
248. Irakkam, M. P. B. D., Joseph, J. H. M., & Kandasamy, M. (2024). Aberrant Hippocampal Neuroregenerative Plasticity in Schizophrenia: Reactive Neuroblastosis as a Possible Pathocellular Mechanism of Hallucination. Neurosignals. https://doi.org/10.33594/000000712
249. Isbell, H. (1956). Studies on Lysergic Acid Diethylamide (LSD-25). A M A Archives of Neurology & Psychiatry. https://doi.org/10.1001/archneurpsyc.1956.02330290012002
250. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
251. Jacob, M. S., Carlen, P. L., Marshman, J. A., & Sellers, E. M. (1981). Phencyclidine Ingestion: Drug Abuse and Psychosis. International Journal of the Addictions. https://doi.org/10.3109/10826088109038866
252. Jaffee, M. S., Broshek, D. K., & Svingos, A. M. (2023). What Is a Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190630119.003.0001
253. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
254. Jalal, B. (2018). The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology. https://doi.org/10.1007/s00213-018-5042-1
255. Jang, J.-H., Jung, K., Kim, J., Jung, I. C., Yoo, H.-R., & Moon, C. (2018). Potential Application of Yokukansan as a Remedy for Parkinson’s Disease. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/1875928
256. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
257. Jarrett, R. B., Schaffer, M., McIntire, D. D., Witt-Browder, A., Kraft, D., & Risser, R. C. (1999). Treatment of Atypical Depression With Cognitive Therapy or Phenelzine. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.56.5.431
258. Jen, J. C. (2015). Familial Hemiplegic Migraine.
259. Jirák, R. (2009). Racionální a neracionální užití antipsychotik v gerontopsychiatrii. Psychiatrie pro praxi.
260. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
261. Joshi, A., Shah, P. S., & Khanna, H. (2023). DIAGNOSTIC CHALLENGES OF HYPERSOMNIA IN AN INDIAN CHILD: A CASE REPORT. Indian Journal Of Applied Research. https://doi.org/10.36106/ijar/5301041
262. Jp, P., Ravella, P., Gelas, P., & Boulétreau, P. (1990). [Sleep and psychological disorders in intensive care units].. PubMed.
263. Jurkić, M. (2011). Opsesivno-kompulzivni poremećaj.
264. Kakunje, A., & Rao, T. S. (2017). Making sense of the role of sense organs in trichotillomania. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.210740
265. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
266. Kane, I., Light, M. J., Osewa, I., Nobler, M. S., & Siddiqi, N. (2017). Acute psychosis with manic features in patient with Fahrs syndrome: A Case report and Clinical review. Neuropsychiatry. https://doi.org/10.4172/neuropsychiatry.1000207
267. Kang, K., & Kim, B. (2019). Neurological Symptoms of Intracranial Hypotension. Journal of the Korean Neurological Association. https://doi.org/10.17340/jkna.2019.2.1
268. Kaplan, H., Sadock, B. J., & Grebb, J. A. (1994). Kaplan and Sadock's synopsis of psychiatry : behavorial sciences, clinical psychiatry. Williams & Wilkins eBooks.
269. Kaplan, P. W. (2003). Delirium and epilepsy. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2003.5.2/pkaplan
270. Kapoor, K. (2003). Novel Potential Antimigraine Compounds: Carotid and Systemic Haemodynamic Effects in a Porcine Model of Migraine.
271. KARADENİZ, S., & KANDİL, S. (2017). Sleepwalking Improved with Fluoxetine Treatment in a Case of Obsessive Compulsive Disorder Accompanied by Sleepwalking. Turkish Journal of Pediatric Disease. https://doi.org/10.12956/tjpd.2017.318
272. Karon, B. P. (1990). The Fear of Understanding Schizophrenia and the Avoidance of the Acutely Disturbed Student. Journal of American College Health. https://doi.org/10.1080/07448481.1990.9936214
273. Kashiwagi, Y. (2011). Know-how and Guidance Regarding Palliative Care from the Viewpoint of a Psychiatrist. Haigan. https://doi.org/10.2482/haigan.51.127
274. Kasper, S. (1997). Angst — Panikstörung. Deutscher Universitätsverlag eBooks. https://doi.org/10.1007/978-3-322-85484-1_3
275. Kato, M. (2022). Current Status and Limitations of Psychiatric Disorders and Pharmacotherapy, and Prospects for Precision Medicine. Proceedings for Annual Meeting of The Japanese Pharmacological Society. https://doi.org/10.1254/jpssuppl.95.0_2-s24-3
276. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
277. Khadka, S., Singh, P., Khadka, M., Chakrabarti, K., Pandit, S., Dhonju, G., & Gautam, S. (2019). A Case Report On Fluoro-Quinolones (Ofloxacin) Induced Psychosis At Nepal Medical College Teaching Hospital. Journal of Psychiatrists Association of Nepal. https://doi.org/10.3126/jpan.v8i2.28029
278. Kim, H. A., Bisdorff, A., Bronstein, A. M., Lempert, T., Rossi-Izquierdo, M., Staab, J. P., Strupp, M., & Kim, J. (2019). Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-190655
279. Kim, S. H., Kim, K. M., Lim, Y. H., Yoo, B. H., Cho, J., & Jun, I.-J. (2022). Psychogenic coma after general anesthesia with remimazolam and remifentanil – a case report. Korean journal of anesthesiology. https://doi.org/10.4097/kja.22242
280. Kimball, A. B., & Grossman, S. A. (2017). Syncope And Related Paroxysmal Spells.
281. Knapp, P., & Lightbody, C. E. (2019). Emotional and Cognitive Changes Following a Stroke. https://doi.org/10.1002/9781119581161.ch11
282. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
283. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2015). A Case of Cannabis Use-Associated Psychotic Disorder Accompanied by Autoscopic Phenomena. Addicta The Turkish Journal on Addictions. https://doi.org/10.15805/addicta.2015.2.1.061e
284. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2016). Use of Modafinil in Psychiatric Disorders. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry.
285. Kokurcan, A., & Atbaşoğlu, C. (2015). [Differential Diagnosis of Schizophrenia: Psychotic Symptoms in Neurodevelopmental Disorders and Psychotic Disorders due to other Medical Conditions].. PubMed.
286. Kondo, T., & Ishiguchi, H. (2007). 3. Drug Induced Dyskinesia. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.96.1621
287. Konrad, K., Firk, C., & Uhlhaas, P. J. (2013). In Reply. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2013.0733b
288. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
289. Kordovan, J. (2015). Farmakološke i nefarmakološke mjere u terapiji nesanice.
290. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
291. Kovalenko, A. L., Sinenchenko, A. G., & Lodyagin, A. N. (2022). [CLINICAL CASE OF ACUTE SEVERE COMBINED POISONING WITH NARCOTIC SUBSTANCES OF DEPENDENT AND PSYCHOSTIMULATING EFFECTS].. PubMed.
292. KOYNER, F. G., Barrera, N. P., Subedi, P., Shrestha, K., & Cerrud‐Rodriguez, R. (2024). When Two Syndromes Collide: Managing Fanconi and Refeeding Syndrome in a Single Patient. Cureus. https://doi.org/10.7759/cureus.52169
293. Krauseneck, T., Krähenmann, O., Heimendahl, J. V., Schelling, G., & Padberg, F. (2007). Psychiatrische Erkrankungen auf der Intensivstation - Teil III: Psychische Reaktionen, affektive Erkrankungen und Angststörungen. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. https://doi.org/10.1055/s-2007-974579
294. Kreek, M. J. (2011). Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2011.06152.x
295. Krystal, A. D. (2007). The Morbidity of Insomnia. CNS Spectrums. https://doi.org/10.1017/s1092852900026110
296. Kumagai, R., & Iseki, E. (2012). [Psychotropic medication of elderly patients].. PubMed.
297. Kuypers, K. P. C. (2024). Microdosing psychedelics in the treatment of ADHD and comorbid disorders. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.44
298. Kızılkılıç, E. K., Kılboz, B. B., & Üçler, S. (2023). Syndrome of Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL): A Case Report - Is there an Association with the COVID-19 Vaccine?. Annals of Indian Academy of Neurology. https://doi.org/10.4103/aian.aian_1002_22
299. Lagi, A. (2011). Syncope and Hypoglycemia. International Journal of Clinical Medicine. https://doi.org/10.4236/ijcm.2011.22023
300. Laili, S. R. (2019). Asuhan Keperawatan Jiwa dengan Kasus Halusinasi Penglihatan di Wilayah Kerja UPTD Puskesmas Kecamatan Sananwetan Kota Blitar.
301. Lam, R. W. (2012). Clinical features and diagnosis. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199692736.003.0004
302. Lambert, T. (2007). Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes.. PubMed.
303. Lammers, M., & Ahmed, A. (2013). Melatonin for Sundown Syndrome and Delirium in Dementia: Is It Effective?. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12296
304. Langguth, B., Bär, R., Wodarz, N., Wittmann, M., & Laufkötter, R. (2011). Paradoxical Reaction in ADHD. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0541a
305. Lassen, J. F., Ravn, H. B., & Lassen, S. F. (1990). [Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms].. PubMed.
306. LATHAM, M. (2006). Colin: A case of health anxiety. Routledge eBooks. https://doi.org/10.4324/9780203966037-23
307. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
308. Lauterbach, E. C. (1997). Long-Term Psychiatric and Neurologic Treatment After a Traumatic Midbrain Lesion. Neurocase. https://doi.org/10.1093/neucas/3.2.95
309. Lauterbach, E. C., & Spears, T. (1997). Long-term psychiatric and neurologic treatment after a traumatic midbrain lesion. Neurocase. https://doi.org/10.1080/13554799708404042
310. Lavigne, G., Blanchet, P., Khoury, S., Carra, M. C., Rouleau, G. A., & Denis, R. (2010). Headache and sleep: guidance in recognition. Douleur et Analgésie. https://doi.org/10.1007/s11724-010-0207-7
311. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
312. Lazaro, Y. M., Molina, R. B., Olivares, L., Pérez, A. M., & Mesián, I. (2016). Paraphrenia: Claiming for its diagnosis. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2151
313. Lee, C., Kim, T. Y., Song, Y. K., Son, Y., & Cheong, Y. K. (2006). Transient Global Amnesia Developed in Recovery Room following General Anesthesia: A case report. Korean Journal of Anesthesiology. https://doi.org/10.4097/kjae.2006.51.1.130
314. Lee, Y. L., Wong, J., & Ng, S. Y. (2022). Delirium in patients following general anaesthesia. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.202228
315. Lenzenweger, M. F. (2018). Schizotypy, schizotypic psychopathology and schizophrenia. World Psychiatry. https://doi.org/10.1002/wps.20479
316. Leong, G. B., Silva, J. A., & Weinstock, R. (2009). Delusions. Wiley Encyclopedia of Forensic Science. https://doi.org/10.1002/9780470061589.fsa256
317. Leong, G. B., Silva, J. A., & Weinstock, R. (2009). Hallucinations. Wiley Encyclopedia of Forensic Science. https://doi.org/10.1002/9780470061589.fsa268
318. Leong, G. B., Silva, J. A., & Weinstock, R. (2012). Hallucinations. Wiley Encyclopedia of Forensic Science. https://doi.org/10.1002/9780470061589.fsa268.pub2
319. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
320. Lidija, G. G. S. (2011). Physiotherapeutic intervention with neurodevelopment risky infants in NICU.
321. Liira, J., Verbeek, J., & Ruotsalainen, J. (2015). Pharmacological Interventions for Sleepiness and Sleep Disturbances Caused by Shift Work. JAMA. https://doi.org/10.1001/jama.2014.18422
322. Lima, J. C. D. (2018). Evidências de projeções indiretas da substância negra compacta para o núcleo retrotrapezóide por meio da substância cinzenta periaquedutal e as alterações respiratórias observadas nesta via em um modelo da doença de Parkinson.. https://doi.org/10.11606/t.42.2018.tde-20092018-135704
323. Lin, Z., Feng, H., Zhang, W., Xiao, G., Chen, J., & Liu, Z. (2025). Correct understanding of the definition and management strategies for refractory hydrocephalus. Chinese Neurosurgical Journal. https://doi.org/10.1186/s41016-025-00403-9
324. Lipowski, Z. J. (1987). Delirium (acute confusional states). JAMA. https://doi.org/10.1001/jama.258.13.1789
325. Liu, C., Tseng, A., & Yang, S. (2004). Chinese Herbal Medicine: Modern Applications of Traditional Formulas.
326. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
327. Llorente, J. M., & Martínez, E. R. (2010). Otros trastornos no motores en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009743
328. Lobo, A., Saz, P., Quintanilla, M., & Gracia‐García, P. (2018). Dementia. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl05
329. Lovati, C. (2013). Sleep apnea headache and headaches with sleep apnea: the importance of being secondary. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2013.853450
330. Lyketsos, C. G. (2012). F1‐01‐02: Tackling overlap of neuropsychiatric symptoms in Alzheimer's and other dementias: Toward a unified approach to evaluation and treatment. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.191
331. Lykouras, L., & Gournellis, R. (2011). [Behavioral and psychological symptoms of dementia and their management].. Psychiatriki.
332. Lyu, J. (2014). Advances in sepsis-associated encephalopathy. Zhongguo xiaoer jijiu yixue. https://doi.org/10.3760/cma.j.issn.1673-4912.2014.03.018
333. López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022). 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.990405
334. López‐Ibor, M. I., López-Ibor, J. J., & Herreros, M. H. (1998). [Landau-Kleffner syndrome (acquired aphasia with epilepsy). Etiopathology and response to treatment with anticonvulsants].. PubMed.
335. Maceira, E., Lesar, T. S., & Smith, H. S. (2012). Medication related nausea and vomiting in palliative medicine.. PubMed. https://doi.org/10.3978/j.issn.2224-5820.2012.07.11
336. Machado, A. S., Dias-Amaral, A., Silva, A., & Grangeia, R. (2020). Psicose Associada a Produtos de Ervanária: Perturbação Delirante Orgânica de Carácter Iatrogénico. Acta Médica Portuguesa. https://doi.org/10.20344/amp.13135
337. Machado, G. G., Miranda, E., Moraes, C. S., Balsan, I. S. G., Bonini, L. V., Siqueira, V., Machado, E. L. J. D., Santos, A. D. D., Campelo, I. K. B., Melo, M. J. O. F. D., Conceição, M. V. D. P. D., Lopes, J. D. V., D’Ângelo, I. F. B., Silva, L. R. S., & Oliveira, M. V. A. D. (2024). ANÁLISE DAS TERAPIAS MEDICAMENTOSAS NA CONDUTA DA ESQUIZOFRENIA. Revista Contemporânea. https://doi.org/10.56083/rcv4n5-244
338. Machek, S. B. (2019). Psychedelics: Overlooked Clinical Tools with Unexplored Ergogenic Potential.
339. Maddocks, I., & Macleod, A. D. (2018). Sleep, sedation and coma. CRC Press eBooks. https://doi.org/10.4324/9781315385532-10
340. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
341. Maglione, J. E., Vahia, I. V., & Jeste, D. V. (2015). Schizophrenia Spectrum and Other Psychotic Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370054.ds11
342. Mailman, R. B., & Murthy, V. (2010). Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?. Current Pharmaceutical Design. https://doi.org/10.2174/138161210790361461
343. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
344. Maldonado, J. R., & Spiegel, D. (2015). Dissociative Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch61
345. Malek, N., & Greene, J. (2014). Cognition enhancers for the treatment of dementia. Scottish Medical Journal. https://doi.org/10.1177/0036933014561948
346. Malikova, M. A. (2024). Schizophrenia: Studying the Influence of Various Factors on the Occurrence and Progression of Disease. European Journal of Medical and Health Research. https://doi.org/10.59324/ejmhr.2024.2(6).29
347. Manford, M. (1998). Complex visual hallucinations. Clinical and neurobiological insights. Brain. https://doi.org/10.1093/brain/121.10.1819
348. Manfredi, R. L., Brennan, R. T., & Cadieux, R. J. (1987). Disorders of Excessive Sleepiness: Narcolepsy and Hypersomnia. Seminars in Neurology. https://doi.org/10.1055/s-2008-1041425
349. Mani, J. (2022). Nonconvulsive status epilepticus (NCSE). Bombay Hospital Journal. https://doi.org/10.15713/ins.bhj.77
350. Manica, A., Leães, C. G. S., Frey, B. N., & Juruena, M. F. (1999). The role of depression in coronary artery disease. Arquivos Brasileiros de Cardiologia. https://doi.org/10.1590/s0066-782x1999000800012
351. Manzo-García, D. M., & Alvarez-Bobadilla, G. M. (2010). Evaluación del estado de conciencia con la prueba de Folstein, en pacientes bajo anestesia general, sometidos a cirugía de columna. Deleted Journal.
352. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
353. Marder (2006). A review of agitation in mental illness: treatment guidelines and current therapies.. PubMed.
354. Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023). Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients. https://doi.org/10.1007/978-3-031-30093-6_4
355. Marques, A. D. L., Alves, L. F., Azevedo, P. H. L. D., Oliveira, M. A. D., Cruz, B. S., Costa, M. F. D. O., Castro, T. I. B. D., & Dogakiuti, J. P. (2022). Abordagem do serviço de emergência para cefaleia não traumática em crianças / Emergency service approach for non-traumatic headache in children. Brazilian Journal of Health Review. https://doi.org/10.34119/bjhrv5n3-283
356. Martin, L. (2015). Special Report Countdown: Comorbidities.
357. Martinotti, G., Petta, G. D., Piro, T., Chillemi, E., & Ferro, F. M. (2024). The exogenous model of psychotic experience induced by novel psychoactive substances: A clinical overview. Emerging Trends in Drugs Addictions and Health. https://doi.org/10.1016/j.etdah.2023.100141
358. Martins, J. R. D. S., Vaz, R., Costa, A., Brás, J., Sousa, R., Abreu, J., Almeida, E., Andrade, R., Castro, N., & Casanova, T. (2023). Postpartum Delirium: A Psychosis Born in the 18th Century. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2398
359. Martín, E. S. S., Juanes, J., Montero, R., & Aguiar, C. S. (2012). Demencia frontotemporal asociada al cromosoma 17 y otros síndromes parkinsonianos asociados a demencia. Revista de Neurología. https://doi.org/10.33588/rn.54s04.2012520
360. Martínez‐Castrillo, J. C., Vela, L., Val, J. D., & Alonso‐Cánovas, A. (2011). Nonmotor Disorders and Their Correlation With Dopamine. The Neurologist. https://doi.org/10.1097/nrl.0b013e318239669f
361. Martínez‐Salio, A., Soler-Algarra, S., Calvo-Garcia, I., & Sánchez-Martín, M. (2007). Síndrome de ingesta nocturna relacionada con el sueño con respuesta al topiramato. Revista de Neurología. https://doi.org/10.33588/rn.4505.2007188
362. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
363. Matsumoto, K., & Ueyama, K. (1994). [Central nervous disease and manic state].. PubMed.
364. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
365. Maćkowiak, M. (2023). Psychedelics action and schizophrenia. Pharmacological Reports. https://doi.org/10.1007/s43440-023-00546-5
366. McCarty, R. (2020). Stress and Schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190697266.003.0008
367. McGuinness, T. M. (2009). Update on Marijuana. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20090902-03
368. McQuillan, R. (2020). Symptoms other than pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0065
369. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
370. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
371. Mehta, U. M., Kumar, C. N., Venkatasubramanian, G., & Thirthalli, J. (2013). Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.meku.112013
372. Melo-Dias, C., Apóstolo, J., & Cardoso, D. (2014). Effectiveness of progressive muscle relaxation training for adults diagnosed with schizophrenia: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2014-1639
373. Mendieta, M. M. Z., Sánchez, J. C., Delgado, R., Chicaiza, K., & Carrasco, D. R. Z. (2023). Search strategies-Characteristics, treatment, and outcomes of Folie a Deux. A systematic review of case report and case series. Figshare. https://doi.org/10.6084/m9.figshare.22256929
374. Meneses, A. (2013). 5-HT systems: emergent targets for memory formation and memory alterations. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2013-0026
375. Menéndez, S. F., González, J. M. G., Antuña, V. Á., & Bobes, J. (2016). La demencia del rey Fernando VI y el año sin rey. Revista de Neurología. https://doi.org/10.33588/rn.6211.2016040
376. Michel, J., Gisselbaek, A., Gauthey, L., & Zelger, G. L. (1993). [Non-compliant drug taking in elderly subjects].. PubMed.
377. Mignot, E. (2011). Narcolepsy. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805267711101010040
378. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
379. Miller, A. E., DeAngelis, T. M., Fabian, M., & Sand, I. K. (2018). A Case of Syncope and Impaired Micturition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190693190.003.0037
380. Milovac, Ž., Pisk, S. V., Silić, A., & Mihanović, M. (2010). Diagnostic dilemma – serotonin syndrome or medication induced delirium:. Socijalna psihijatrija.
381. Milovanović, S., Ćulafić, Đ. M., Leposavić, L., & Vojinovic, V. C. (2004). Hepatic encephalopathy in consultative psychiatry: Experience with chlomethiazole. Engrami.
382. Mizukami, K., Naito, Y., Yoshida, M., Nakanishi, T., & Koizumi, J. (1990). Mental Disorders Induced by Carbamazepine. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.1990.tb00441.x
383. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
384. Modebelu, U., Nargarathan, P. K. M., Marleime, K., & Ramesh, K. (2019). Pharmacologic Therapy for Neonatal Abstinence Syndrome. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v9i3.2900
385. Modugno, N., Lena, F., Biasio, F. D., Cerrone, G. E., Ruggieri, S., & Fornai, F. (2013). A clinical overview of non-motor symptoms in Parkinson's Disease.. PubMed.
386. Molloy, A., Williams, L., Farrell, M., & O’Riordan, S. (2014). Hereditary Diffuse Leucoencephalopathy and Spheroids Resulting From a Mutation in <i>CSF1R</i>: A Rare Cause of Parkinsonism. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12033
387. Moncrieff, J. (2015). Antidepressants: misnamed and misrepresented. World Psychiatry. https://doi.org/10.1002/wps.20243
388. Montes, A. B., & Rey, J. A. (2009). Iloperidone (Fanapt): An FDA-Approved Treatment Option for Schizophrenia. P & T.
389. Morin, A. K., Jarvis, C. I., & Lynch, A. M. (2006). Therapeutic Options for Sleep‐Maintenance and Sleep‐Onset Insomnia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.27.1.89
390. Mossaheb, N., Schloegelhofer, M., Schaefer, M., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G., & Amminger, G. P. (2012). Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-215-5_9
391. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
392. Mouta, S., Vaz, I. F., Pires, M., Ramos, S. R., & Figueiredo, D. (2023). What do we know about pseudodementia?. General Psychiatry. https://doi.org/10.1136/gpsych-2022-100939
393. Mueller‐Pfeiffer, C., & Wittmann, L. (2013). Preliminary Investigation of the Reliability and Validity of the German Version of the State Scale of Dissociation (SSD). Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000106
394. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
395. Murakami, M., & Matsuno, T. (2010). Musculoskeletal Chronic Pain and Psychosocial Stress. Journal of Nihon University Medical Association. https://doi.org/10.4264/numa.69.183
396. Musálek, M. (2011). Pathologisches Spielen: Impulskontrollstörung oder Sucht?. Suchttherapie. https://doi.org/10.1055/s-0031-1284655
397. Muñoz-Lara, J. (2015). Depresión en la persona adulta mayor institucionalizada: Un nuevo reto. Revista Hispanoamericana de Ciencias de la Salud (RHCS).
398. Mystakidou, K., Panagiotou, I., Parpa, E., & Tsilika, E. (2015). Sleep disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199656097.003.0086
399. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
400. Müller, K., Gehl, A., Ottens, R., & Püschel, K. (2011). [Suicide by hypothermia with intentional partial undressing].. PubMed.
401. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
402. Nagireddy, R. B. R., & Joshi, D. (2020). Phenytoin induced chorea: an uncommon manifestation. Authorea (Authorea). https://doi.org/10.22541/au.159109589.94248103
403. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
404. Nakamura, M., & Inoue, Y. (2013). [Characteristic and treatment of insomnia in dementia].. PubMed.
405. Nakano, M., Funayama, M., Takata, T., Wakisaka, R., Koyama, G., Koreki, A., Ishida, T., Uchida, H., & Mimura, M. (2024). Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05846-5
406. Namlı, Z., ÖZBAY, A., & Tamam, L. (2022). Yetişkin Ayrılma Anksiyetesi Bozukluğu: Bir Gözden Geçirme. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. https://doi.org/10.18863/pgy.940071
407. Nasirian, M., Banazadeh, N., & Kheradmand, A. (2009). Rare variant of lycanthropy and ecstasy.. PubMed.
408. Nasrallah, H. A. (2012). Impaired Mental Proprioception in Schizophrenia. Current psychiatry.
409. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
410. Nemr, K., Simões-Zenari, M., Marques, S. F., Cortez, J. P., & Silva, A. L. D. (2010). Disfonia psicogênica associada a outras doenças: desafio para o tratamento fonoaudiológico**** Psychogenic dysphonia associated to other diseases: a challenge for speech therapy.
411. Neven, A., & Blom, J. D. (2014). [Synesthesias in the context of hallucinogen-induced persistent perception disorder following the use of lsd].. PubMed.
412. Nikić, P., Zidverc‐Trajkovic, J., Andrić, B., Milinković, M., & Stojimirović, B. (2009). Caffeine-withdrawal headache induced by hemodialysis. The Journal of Headache and Pain. https://doi.org/10.1007/s10194-009-0119-1
413. Nosek, M. A., & Howland, C. A. (1998). Abuse and Women with Disabilities.
414. Nozawa, T. (2002). Abnormal Behavior During Sleep. Relationships between Parasomnias and Epilepsy.. Journal of the Japan Epilepsy Society. https://doi.org/10.3805/jjes.20.3
415. Ohry, A. (2011). [On hallucinations, bizarre sensations, phantom phenomena and body-image disturbances].. PubMed.
416. Ojeda, B. S., Salazar, A., Dueñas, W. A. M., & Failde, I. (2011). El deterioro cognitivo: un factor a tener en cuenta en la evaluación e intervención de pacientes con dolor crónico. Revista de la Sociedad Española del Dolor.
417. Olshansky, B., Feigofsky, S., & Cannom, D. S. (2018). Is it bradycardia or something else causing symptoms?. HeartRhythm Case Reports. https://doi.org/10.1016/j.hrcr.2018.09.011
418. Orsolini, L., Valchera, A., Papanti, D., Vecchiotti, R., & Berardis, D. D. (2016). The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD). European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1060
419. O’Connor, F. G., & Levine, B. D. (2015). Syncope in Athletes of Cardiac Origin. Current Sports Medicine Reports. https://doi.org/10.1097/01.csmr.0000465136.70746.5b
420. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
421. Pagel, J., Pandi‐Perumal, S. R., & Monti, J. M. (2018). Treating insomnia with medications. Sleep Science and Practice. https://doi.org/10.1186/s41606-018-0025-z
422. Pappagallo, M. (1998). The Concept of Pseudotolerance to Opioids. Journal of Pharmaceutical Care in Pain & Symptom Control. https://doi.org/10.1300/j088v06n02_07
423. Paradela, E. M. P. (2011). Depressão em idosos. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE). https://doi.org/10.12957/rhupe.2011.8850
424. Parker, R. S. (2012). Chronic Posttraumatic Disorders of Consciousness. CRC Press eBooks. https://doi.org/10.1201/b10562-14
425. Pary, R., Lippmann, S., & Tobias, C. R. (1994). Obsessive-compulsive disorder. Postgraduate Medicine. https://doi.org/10.1080/00325481.1994.11945941
426. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
427. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
428. Paulig, M. (2006). Kognitive Störungen bei idiopathischem Parkinson-Syndrom. psychoneuro. https://doi.org/10.1055/s-2006-955079
429. Paulus, W. J., Reimers, C. D., & Steinhoff, B. J. (2000). Dystonien (unwillkürliche Muskelbewegungen). Steinkopff eBooks. https://doi.org/10.1007/978-3-642-57726-0_16
430. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
431. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
432. Pennes, H. H., & Hoch, P. H. (1957). PSYCHOTOMIMETICS, CLINICAL AND THEORETICAL CONSIDERATIONS: HARMINE, WIN-2299 AND NALLINE. American Journal of Psychiatry. https://doi.org/10.1176/ajp.113.10.887
433. Peralta, C. (2013). [Neuropsychiatric non motor symptoms of Parkinson's disease].. PubMed.
434. Perrott, J., & Burry, L. (2015). Has the Drug of Choice for Treating Critical Illness Delirium Been Established?. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v68i5.1494
435. Perry, E., Mosimann, U. P., & Collerton, D. (2014). The treatment of visual hallucinations at present and in the future. https://doi.org/10.1002/9781118892794.ch14
436. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
437. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
438. Phu, T., Remmers, A., Schytz, H. W., Schankin, C. J., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. (2018). Red and orange flags for secondary headaches in clinical practice. Neurology. https://doi.org/10.1212/wnl.0000000000006697
439. Piccolo, A. C., Campos, L. M. G., & Audi, M. (2025). RELAÇÃO ENTRE A QUALIDADE DO SONO, PERCEPÇÃO CORPORAL E OS SINTOMAS MOTORES E SENSITIVOS EM PESSOAS COM ESCLEROSE MÚLTIPLA REMITENTE-RECORRENTE. Aracê.. https://doi.org/10.56238/arev7n8-002
440. Piróg-Balcerzak, A., Habrat, B., & Mierzejewski, P. (2015). Misuse and abuse of quetiapine. Psychiatria Polska. https://doi.org/10.12740/pp/32923
441. Poewe, W., & Jankovic, J. (2014). Preface. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175845.001
442. Pontius, A. A. (1990). INFANTICIDE IN LIMBIC (?) PSYCHOTIC TRIGGER REACTION IN A MAN WITH JACKSONIAN AND PETIT MAL (?) SEIZURES: 'KINDLING' BY TRAUMATIC EXPERIENCES. Psychological Reports. https://doi.org/10.2466/pr0.67.7.935-945
443. Pontius, A. A. (1993). NEUROPSYCHIATRIC UPDATE OF THE CRIME "PROFILE" AND "SIGNATURE" IN SINGLE OR SERIAL HOMICIDES: RULE OUT LIMBIC PSYCHOTIC TRIGGER REACTION. Psychological Reports. https://doi.org/10.2466/pr0.1993.73.3.875
444. Pontius, A. A. (1993). Neuropsychiatric Update of the Crime “Profile” and “Signature” in Single or Serial Homicides: Rule out Limbic Psychotic Trigger Reaction<sup>1</sup>. Psychological Reports. https://doi.org/10.1177/00332941930733pt125
445. Poornima, S. (2018). Psychology Case Record.
446. Prajapati, B., Agarwal, A., Garg, D., Garg, A., Pandit, A., Radhakrishnan, D. M., & Srivastava, A. (2024). Delayed post-hypoxic parkinsonism with leukoencephalopathy associated with carbon monoxide poisoning. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_37_24
447. Pranami, D. M., Kaushal, J., & Bhutani, G. (2013). Insomnia: Current Treatment and Recent Advances. Journal of Pharmaceutical Research.
448. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
449. Pressman, M. R. (2013). Complex (Including Violent) Sleep Behavior. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199795161.003.0036
450. Provini, F., Lombardi, C., & Lugaresi, E. (2005). Insomnia in Neurological Diseases. Seminars in Neurology. https://doi.org/10.1055/s-2005-867074
451. Pysden, K. (2015). Alternating hemiplegia of childhood. Journal of Pediatric Neurology. https://doi.org/10.3233/jpn-2010-0337
452. Páez, J. L. V., Mogro, E. B. I., López, P. C., & Galarza, C. G. S. (2018). Leucoencefalopatía posterior reversible: Reporte de un caso. Pro Sciences Revista de Producción Ciencias e Investigación. https://doi.org/10.29018/issn.2588-1000vol2iss12.2018pp31-33
453. Pérez, Y. M. M., Ortega, D. L. G., & Torres, S. V. L. (2022). AGITACIÓN PSICOMOTRIZ. PUERTO MADERO EDITORIAL eBooks. https://doi.org/10.55204/pmea.3.c10
454. Pérez-Rodríguez, V., Gadea, M. O., Caronna, E., & Urrutia, A. R. (2018). Clínica alucinatoria secundaria a enfermedad médica: características clínicas y manejo. DOAJ (DOAJ: Directory of Open Access Journals). https://doi.org/10.34810/psicosompsiquiatrnum0404
455. Qamar, A., Kotha, K., & Ioachimescu, O. C. (2011). Obstructive Sleep Apnea. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805267711101010021
456. Quadri, M. (2013). Finding Genes for Parkinsonism.
457. Quesada, M. (2022). Vértigo y mareo. Actualización en Medicina de Familia. https://doi.org/10.55783/amf.181036
458. Rachmani, S., & Mayasari, D. (2017). Kombinasi Farmakoterapi dan Psikoterapi Pada Pengobatan Episode Depresif Sedang Dengan Gejala Somatis. Jurnal Medula.
459. Radovanovi, M. R., Milovanovi, D. R., & Radovanovi, M. S. (2012). Heroin addict with gangrene of the extremities, rhabdomyolysis and severe hyperkalemia Heroinski zavisnik sa gangrenom ekstremiteta, rabdomiolizom i teškom hiperkalemijom.
460. Rahmani, M., Ahmadi, S., & Moghaddam, H. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose.
461. Rahmani, S. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose Methamphetamine. Journal of Clinical Toxicology. https://doi.org/10.4172/2161-0495.1000111
462. Rani, M. K. S., Fathima, S. T., Gayathri, S. L., Pavani, M., & Swathi, Y. (2022). Detection of Autism Spectrum Disorder using Machine Learning. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-7600
463. Rasmussen, S., & Kristensen, M. B. (1977). Choreoathetosis during Phenytoin Treatment. Acta Medica Scandinavica. https://doi.org/10.1111/j.0954-6820.1977.tb15691.x
464. Rastegar, D. A. (2020). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0009
465. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
466. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
467. Rauniyar, S., Raj, P. D., & Sapkale, B. (2023). Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential. Cureus. https://doi.org/10.7759/cureus.48719
468. Ravichand, M., & Radtke, R. A. (2013). Approach to a Patient with Narcolepsy. https://doi.org/10.1002/9781118764152.ch5
469. Račkauskaitė, J., Danilevičiūtė, V., & Navickas, A. (2014). Haliucinacijų etiologijos aspektai. Sveikatos mokslai. https://doi.org/10.5200/sm-hs.2014.013
470. Realpe, B. L. C. (2013). Estudio comparativo de la acción psicofarmacológica y analgésica de extractos de plantas de uso terapéutico tradicional con antidepresivos inhibidores selectivos de la recaptación de monoaminas.
471. Reid, K. J., & Zee, P. C. (2004). Circadian Rhythm Disorders. Seminars in Neurology. https://doi.org/10.1055/s-2004-835063
472. Resch, M. (2010). The psychological factors affecting athletic performance. Orvosi Hetilap. https://doi.org/10.1556/oh.2010.28890
473. Reuber, M., Schachter, S. C., Elger, C. E., & Altrup, U. (2009). Conditions Associated With Epilepsy. https://doi.org/10.1093/oso/9780195379532.003.0005
474. Reuter, I., Mehnert, S., Oechsner, M., & Engelhardt, M. (2011). Cognitive Rehabilitation in Parkinson's Disease Using Neuropsychological Training, Transfer Training and Sports Therapy. InTech eBooks. https://doi.org/10.5772/17685
475. Revonsuo, A., Kallio, S., & Sikka, P. (2009). What is an altered state of consciousness?. Philosophical Psychology. https://doi.org/10.1080/09515080902802850
476. Reynolds, E., & Wilson, J. V. K. (2014). Neurology and psychiatry in Babylon. Brain. https://doi.org/10.1093/brain/awu192
477. Richter, W., & Otto, C. (1997). [Hypoglycemia. Symptoms, differential diagnosis, therapy].. PubMed.
478. Rico, B. (2012). Finding a druggable target for schizophrenia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1209389109
479. Riedlinger, T. J., & Riedlinger, J. (1994). Psychedelic and Entactogenic Drugs in the Treatment of Depression. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.1994.10472600
480. Rinkel, M., Deshon, H. J., Hyde, R. W., & Solomon, H. C. (1952). EXPERIMENTAL SCHIZOPHRENIA-LIKE SYMPTOMS. American Journal of Psychiatry. https://doi.org/10.1176/ajp.108.8.572
481. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
482. Rj, T. (2002). [Complex visual hallucinations in partially sighted elderly: Charles Bonnet syndrome].. PubMed.
483. Rohmayanti, I. D., & Kurniawan, S. N. (2023). POST HERPETIC NEURALGIA. JPHV (Journal of Pain Vertigo and Headache). https://doi.org/10.21776/ub.jphv.2023.004.01.1
484. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
485. Rooney, S., & Horvat, C. M. (2024). Decrypting Sepsis-Associated Brain Dysfunction: A Computational Phenotype That Can Hack It*. Pediatric Critical Care Medicine. https://doi.org/10.1097/pcc.0000000000003549
486. Rosenberg, D. L., & Latorre, J. G. (2015). Hearing One’s Voice in Your Speech. The Neurologist. https://doi.org/10.1097/nrl.0000000000000069
487. Rossi, M., Farcy, N., Starkstein, S., & Merello, M. (2019). Nosology and Phenomenology of Psychosis in Movement Disorders. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12882
488. Roth, T. (2007). Introduction. Narcolepsy and Excessive Daytime Sleepiness: From the Bench to the Bedside. The Primary Care Companion To The Journal of Clinical Psychiatry.
489. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
490. Rubiales, Á. S., Duarte, F. B., & Valle, M. L. D. (2015). [Do we need a more precise definition of what sedation is?].. PubMed.
491. Rubiales, Á. S., Duarte, F. J. B., & Valle, M. L. D. (2015). Es necesario precisar el concepto de sedación. Cuadernos de bioética/Cuadernos de bioética.
492. Rubin, J. N. (2018). CONSISTENT PATTERNS IN SECONDARY HEALTH EFFECTS OF DISASTERS. Abstracts with programs - Geological Society of America. https://doi.org/10.1130/abs/2018am-319679
493. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
494. Ruggieri, V., & Arberas, C. (2013). [Non-epileptic motor paroxysmal phenomena in wakefulness in childhood].. PubMed.
495. Ružić, M. (2016). Poremećaj glasa kod osoba treće životne dobi.
496. Saal, D. P., Overdijk, M. J. J., Thijs, R. D., & Dijk, J. G. G. V. (2015). [Unexplained loss of consciousness: the diagnosis is never based on one symptom].. PubMed.
497. Sahli, H., Seddik, L., & Rémy, P. (2018). [Non-motor symptoms of Parkinson disease and their management].. PubMed.
498. Salama, A. Z., Dabash, M. R., Elayan, A., Saadeh, S., & Ikhmayyes, I. (2024). Dissociative Trance Led to a Catastrophe: A Case Report. Cureus. https://doi.org/10.7759/cureus.76458
499. Salani, D., Albuja, L. D., & Zdanowicz, M. M. (2018). The Explosion of a New Designer Drug, Flakka. Journal of Addictions Nursing. https://doi.org/10.1097/jan.0000000000000252
500. Salaspuro, M. (2009). [Intoxicated patient at the emergency department and referral to treatment].. PubMed.
501. Salazar, W. B. P., Israe, C. M. L. G., Antonio, V. V. R., Sofía, S. S. F., & Austreberto, I. Q. R. (2023). Hyperactive and Hypoactive Delirium: What we know so Far. International Journal of Medical Science and Clinical Research Studies. https://doi.org/10.47191/ijmscrs/v3-i7-04
502. Sardiani, S. (2023). Aplikasi Asuhan Keperawatan Jiwa Pada Tn. A Dengan Gangguan Persepsi Sensori:Halusinasi Pendengaran Diruangan Dolok Sanggul II. https://doi.org/10.31219/osf.io/kyqd2
503. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
504. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
505. Saver, J. L., & Rabin, J. S. (1997). The neural substrates of religious experience. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.9.3.498
506. Sazonov, S. (2014). EPA-0651 – The complexity of psychopathological symptom as a possible indication of mental disease's etiology. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78023-x
507. Schildkrout, B. (2011). Specific Mental Signs and Symptoms. https://doi.org/10.1002/9781118083598.ch9
508. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
509. Schildkrout, B. (2014). Delusional Thought Content. https://doi.org/10.1002/9781394260447.ch7
510. Schildkrout, B. (2014). Disease #51: Periodic Limb Movements of Sleep. https://doi.org/10.1002/9781394260447.ch79
511. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
512. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
513. Schneck, H., & Rupreht, J. (1989). Central anticholinergic syndrome (CAS) in anesthesia and intensive care.. PubMed.
514. Schneider, U., Paetzold, W., Emrich, H. M., & Oehlschläger, P. (1999). [Angel trumpets: case report of drug-induced psychosis caused by Brugmansia insigniis].. PubMed.
515. Schneir, A., & Clark, R. F. (2007). The Role of Illicit Drug Use in Sudden In-Custody Death. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-015-7_6
516. Schäfer, I., Kurth, R., & Gerhardt, H. (2011). Posttraumatische und psychotische Symptome bei schwer traumatisierten Patienten. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0031-1281801
517. Schönfeldt‐Lecuona, C., Wolf, R. C., Osterfeld, N., Vasić, N., Connemann, B. J., Schmid, M., & Freudenmann, R. W. (2009). Pregabalin in the Treatment of Schizophrenic Anxiety. Pharmacopsychiatry. https://doi.org/10.1055/s-0028-1112128
518. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
519. Seeman, P., & Seeman, M. V. (2011). Schizophrenia and the supersensitive synapse. Neuropsychiatry. https://doi.org/10.2217/npy.11.18
520. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
521. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
522. Seok-Joon, J., Hyo-Ju, H., Jae-Ho, S., Haedeun, J., Chang-Jae, K., & Mee-Young, C. (2018). Unusual Uncontrolled Emergence Delirium in a Young Adult after Open Bursectomy.
523. Seritan, A. L., Ortigas, M., Seritan, S., Bourgeois, J. A., & Hagerman, R. J. (2013). Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews. https://doi.org/10.2174/157340013805289699
524. Seritan, A. L., Ortigas, M., Seritan, S., Bourgeois, J. A., & Hagerman, R. J. (2013). Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews. https://doi.org/10.2174/1573400511309010009
525. Shaikh, A., Sirajuddin, S. M., Mukadam, M., & Ansari, S. A. (2017). Therapeutic Effect of “Nutool” in the Management of Sehar (Insomnia): A Review. https://doi.org/10.37591/rrjoush.v4i3.51
526. Sharma, A. K., Rani, E., Waheed, A., & Rajput, S. K. (2015). Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions. Journal of Epilepsy Research. https://doi.org/10.14581/jer.15001
527. Sharpe, M. (2006). The symptom of generalised fatigue. Practical Neurology. https://doi.org/10.1136/jnnp.2006.088997
528. Sharpe, M. (2010). Chronic fatigue syndrome (postviral fatigue syndrome, neurasthenia, and myalgic encephalomyelitis). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260504
529. SheikhBahaei, S., Farhan, M., & Maguire, G. A. (2022). Improvement of stuttering after administration of methylphenidate - a case report. Personalized Medicine in Psychiatry. https://doi.org/10.1016/j.pmip.2022.100092
530. Sher, L. (2015). Parental alienation: the impact on men’s mental health. International Journal of Adolescent Medicine and Health. https://doi.org/10.1515/ijamh-2015-0083
531. Shibasaki, H., & Hallett, M. (2016). Psychogenic Neurologic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190240974.003.0026
532. Shih, T., & Bazil, C. W. (2005). Treatment of Generalized Convulsive Status Epilepticus. Humana Press eBooks. https://doi.org/10.1385/1-59259-945-1:265
533. SHOWALTER, C., & Thornton, W. E. (1977). Clinical pharmacology of phencyclidine toxicity. American Journal of Psychiatry. https://doi.org/10.1176/ajp.134.11.1234
534. Siddiqui, J. A., Qureshi, S. F., & Ghamdi, A. K. A. (2017). Alien Abductions: A Case of Sleep Paralysis. Sleep and Hypnosis. https://doi.org/10.5350/sleep.hypn.2017.19.0144
535. Siemiński, M., Skorupa, Ł., & Wiśniewska-Skorupa, K. (2019). Diagnostyka i terapia bezsenności w praktyce ogólnolekarskiej. Część II: Terapia bezsenności. Forum Medycyny Rodzinnej.
536. Silva, A. C. D., Davoglio, L. M. D. P., Federisi, A., Aguiar, A. L. D., Garcia, A. L. F., Dias, C. R. M., Davoglio, G. M. D. P., Stábile, I. D. S. B., Neto, J. G., Abreu, L. M. D. A., Carvalho, E. L. D., Fabro, P. S., & Contrucci, B. A. (2024). Transtorno do Déficit de Atenção e Hiperatividade em pacientes com fenilcetonúria: revisão bibliográfica. Brazilian Journal of Health Review. https://doi.org/10.34119/bjhrv7n4-098
537. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
538. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
539. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
540. Simon, C., Everitt, H., Dorp, F. V., & Burkes, M. (2014). Neurology. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199671038.003.0016
541. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
542. Sinha, S., Moss, A. J., & Calkins, H. (2007). The etiology of sudden death. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544828.014
543. Smith, H. S. (2007). Hibernating Peripheral Nerve. Journal of Neuropathic Pain & Symptom Palliation. https://doi.org/10.1300/j426v02n02_02
544. Smith, M. (2022). Addiction as a Sui Generis Force. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2022.13.00708
545. Smith, M. B. (2023). Addiction as a Sui Generis Force: An Opinion Overview. https://doi.org/10.9734/bpi/nramms/v3/6349a
546. Smith, P. J., & Blumenthal, J. A. (2015). Exercise and Physical Activity in the Prevention and Treatment of Depression. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch8
547. Smith, S. S. (2019). Insomnia and Clinical Sleep Disturbance in Later Life. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.419
548. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
549. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
550. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
551. Solorzano, J. M. M., Quijije, J. K. L., Pin, T. D. R. M., & Vera, J. V. C. (2020). Causas y efectos de los pacientes diagnosticados con el mal de Parkinson. RECIMUNDO. https://doi.org/10.26820/recimundo/4.(4).octubre.2020.496-508
552. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
553. Sommer, I. E., Koops, S., & Blom, J. D. (2012). Comparison of auditory hallucinations across different disorders and syndromes. Neuropsychiatry. https://doi.org/10.2217/npy.12.2
554. Soyka, M. (2006). Alkoholhalluzinose und Eifersuchtswahn. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2005-915641
555. Soyka, M. (2009). Psychotische Störungen durch Alkohol. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628675
556. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
557. Sprigings, D. (2018). Delirium (acute confusional state). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199568741.003.0041
558. Stahl, S. M., & Morrissette, D. A. (2018). Treatment of Secondary Behavioral Symptoms of Dementia. https://doi.org/10.1017/9781107706842.008
559. Stanciu, C. N., & Penders, T. M. (2016). Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case. Current Psychiatry Reviews. https://doi.org/10.2174/1573400512999160803102947
560. Steefan, J. M., Siddesha, G., & Naveen, A. (2023). Adverse Effects of Antipsychotic Drugs - A Review. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20230916
561. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
562. Steinlin, M., & Oesch, V. (2006). Diagnostic errors in shunt dysfunction. Neuropediatrics. https://doi.org/10.1055/s-2006-973978
563. Stoller, K. B. (2015). Psychiatric Co-occurring Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0015
564. Stone, J., & Carson, A. (2015). Conversion Disorder/Functional Neurological Disorder. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp009
565. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
566. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
567. Sugimoto, A., Futamura, A., & Kawamura, M. (2013). [Epilepsy and cognitive dysfunction].. PubMed.
568. Sunarti, S., & Helena, H. (2018). Gangguan Tidur pada Lanjut Usia. Journal of Islamic Medicine. https://doi.org/10.18860/jim.v2i1.5009
569. Sunshine, A. B., & McClellan, J. (2023). Practitioner Review: Psychosis in children and adolescents. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/jcpp.13777
570. Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017). Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. Mental Health Clinician. https://doi.org/10.9740/mhc.2017.07.156
571. Szabo, C. P. (2011). Common adverse drug reactions with psychiatric medications and an approach to their management : main article. CME: Your SA Journal of CPD.
572. Szazz, T. (1993). Crazy talk: Thought disorder or psychiatric arrogance?. British Journal of Medical Psychology. https://doi.org/10.1111/j.2044-8341.1993.tb01726.x
573. Szerman, N., Ferre, F., Basurte-Villamor, I., Vega, P., Mesías, B., Marín-Navarrete, R., & Arango, C. (2020). Gambling Dual Disorder: A Dual Disorder and Clinical Neuroscience Perspective. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2020.589155
574. Szkodny, L. E., Jacobson, N. C., Llera, S. J., & Newman, M. G. (2014). Generalized Anxiety Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg19
575. Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K., Evans, V. D., Fasano, C., & Muir, O. S. (2023). Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview. https://doi.org/10.31234/osf.io/byms6
576. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
577. Tamam, L., & Zengin, M. (2011). Aralikli Patlayici Bozukluk Intermittent Explosive Disorder.
578. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
579. Tani, M., & Iwanami, A. (2013). [Disorder of train of thought in the elderly].. PubMed.
580. Taylor, R. L. (1970). Management of "bad trips" in an evolving drug scene. JAMA. https://doi.org/10.1001/jama.213.3.422
581. Tedyanto, E. H., Adnyana, I. M. O., & Widyadharma, I. P. E. (2023). Tension-type Headache and Migraine as Manifestations of Chronic Post-Traumatic Headache. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v50i2.528
582. Teitelbaum, P., Pellis, S. M., & DeVietti, T. L. (1990). Disintegration into stereotypy induced by drugs or brain damage: a microdescriptive behavioural analysis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198521600.003.0007
583. Thakurta, R. G., Sarkar, S., Debnath, A., & Mondal, S. (2014). Assaulting the Psychiatrist : A Rare Case of Fregoli syndrome. Bengal Journal of Psychiatry. https://doi.org/10.51332/bjp.2014.v19.i2.56
584. Thomas, H. (1993). Psychiatric Symptoms in Cannabis Users. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.163.2.141
585. Tickner, N., Apps, J., Keady, S., & Sutcliffe, A. (2012). An overview of drug therapies used in the treatment of dystonia and spasticity in children. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/archdischild-2011-301170
586. Timperley, J., Leeson, P., Mitchell, A. R., & Betts, T. (2007). Chapter 6 Troubleshooting pacemakers. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198571322.003.0006
587. Todd, O., & Teale, E. (2016). Delirium: a guide for the general physician. Clinical Medicine. https://doi.org/10.7861/clinmedicine.16-6-s98
588. Todder, D., & Baune, B. T. (2007). Recurrence of suicidal ideation due to treatment with antidepressants in anxiety disorder: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/1752-1947-1-166
589. Torpy, J. M. (2010). Delirium. JAMA. https://doi.org/10.1001/jama.304.7.814
590. Townsend, M. C. (2004). Nursing diagnoses in psychiatric nursing : care plans and psychotropic medications. F.A. Davis Co. eBooks.
591. Tranel, D., McNutt, A., & Bechara, A. (2012). Smoking Cessation After Brain Damage Does Not Lead to Increased Depression. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0b013e3182492a9c
592. Turki, T. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report. Journal of King Abdulaziz University-Medical Sciences. https://doi.org/10.4197/med.10-1.12
593. Turki, T. A. A., & Arabia, S. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report.
594. Unknown (2015). America's Children and the Environment: Neurodevelopmental Disorders (Excerpt from the Third Edition). Apple Academic Press eBooks. https://doi.org/10.1201/b18030-7
595. Unknown (2015). Anxiety Disorders. https://doi.org/10.1002/9781118385777.ch8
596. Unknown (2019). Dysautonomia. Definitions. https://doi.org/10.32388/267274
597. Unknown (2019). Encephalopathy. Definitions. https://doi.org/10.32388/476507
598. Unknown (2019). Epilepsy. Definitions. https://doi.org/10.32388/025983
599. Unknown (2019). Hypersomnia. Definitions. https://doi.org/10.32388/969498
600. Unknown (2019). Traumatic Brain Injury. Definitions. https://doi.org/10.32388/973439
601. Utari, F. P., Suyanti, T. S., & Karyawati, T. (2023). Asuhan Keperawatan Jiwa Pada Tn.M Dengan Masalah Utama Resiko Perilaku Kekerasan Akibat : Skizofrenia Tak Terinci Di Ruang Srikandi RSJD Dr.Amino Gondohutomo Provinsi Jawa Tengah. DIAGNOSA Jurnal Ilmu Kesehatan dan Keperawatan. https://doi.org/10.59581/diagnosa-widyakarya.v1i4.1305
602. Uysal, C., & Albayrak, Y. (2013). IMIPRAMINE INDUCED ACUTE DYSTONIA IN A CHILD WITH ENURESIS NOCTURNA.
603. Vallée, L., & Pandit, F. (1991). [Hyperkinetic disorders with attention deficit. Diagnostic and therapeutic approach].. PubMed.
604. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
605. Vataja, R., & Leppävuori, A. (2012). [Assessment and treatment of conversion disorder: the most fascinating borderline of psychiatry and neurology].. PubMed.
606. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
607. Venkataraman, R., Patodia, S., & Thiriveedhi, R. N. (2023). Thrombocytopenia in the Critically Ill: An Animal with Several Heads. Indian Journal of Critical Care Case Report. https://doi.org/10.5005/jp-journals-11006-0089
608. Vi, R. (2006). [Acute glaucine syndrome in the physician's practice: the clinical picture and potential danger].. PubMed.
609. Vicente, M. O., Gutiérrez, L. E. J. F., & Oves, M. I. R. (2011). ALCOHOLISMO CONSECUTIVO AL TRASTORNO DE PÁNICO. DOAJ (DOAJ: Directory of Open Access Journals).
610. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
611. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
612. Vitiello, B., Zuddas, A., & Masi, G. (2006). Pharmacologic treatment of children and adolescents with attention deficit hyperactivity disorder. CRC Press eBooks. https://doi.org/10.1201/b14454-11
613. Volel, B. A., & Petelin, D. S. (2019). Modern concepts about insomnia in mental disorders: clinical aspects. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro201911904263
614. Volkow, N. D., & Wolf, A. (1991). THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.. Brookhaven National Laboratory eBooks.
615. Wahyuningsih, S., Nurun, N., Ainul, A., Rendra, R., & Dwiki, D. (2020). Relaksasi Nafas Dalam Terhadap Tingkat Kecemasan Pada Lansia Yang Menderita Hipertensi Di RT 03 RW 09 Kelurahan Slipi Palmerah Jakarta Barat. JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM). https://doi.org/10.33024/jkpm.v3i2.3194
616. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
617. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
618. Walton, J. C., & Miller, J. M. (1998). Evaluating physical and behavioral changes in older adults.. PubMed.
619. Wang, Y., Sun, Q., Tang, Q., Zhang, Y., Tang, M., Wang, D., & Wang, Z. (2023). Progress of autonomic disturbances in narcolepsy type 1. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1107632
620. Wasti, A. Z. (2025). Psychedelics’ Intoxicating Impact and Behavioural Dynamics. IntechOpen eBooks. https://doi.org/10.5772/intechopen.1011743
621. Weaver, M. F. (2015). Prescription Sedative Misuse and Abuse.. PubMed.
622. Weaver, M. F., Heads, A. M., & Faillace, L. A. (2024). Mood Disorders and Comorbid Substance Use Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.013
623. Weber, S. (2007). DISSOCIATIVE SYMPTOM DISORDERS IN ADVANCED NURSING PRACTICE: BACKGROUND, TREATMENT, AND INSTRUMENTATION TO ASSESS SYMPTOMS. Issues in Mental Health Nursing. https://doi.org/10.1080/01612840701522085
624. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
625. Werdenich, W., & Padlesak, S. (2000). &lt;F63&gt; Abnorme Gewohnheiten und Störungen der Impulskontrolle. https://doi.org/10.1007/978-3-7091-3768-0_25
626. Werner, F. M., & Coveñas, R. (2016). Additional Antidepressant Pharmacotherapies According to a Neural Network. Brain Disorders & Therapy. https://doi.org/10.4172/2168-975x.1000203
627. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
628. Willner, P. (1984). Drugs, Biochemistry, and Conscious Experience: Toward a Theory of Psychopharmacology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1984.0009
629. Wilson, K. C., & Saukkonen, J. (2004). Acute Respiratory Failure from Abused Substances. Journal of Intensive Care Medicine. https://doi.org/10.1177/0885066604263918
630. Winters, W. D. (1976). Effects of Drugs on the Electrical Activity of the Brain: Anesthetics. The Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pa.16.040176.002213
631. Woźniak, J., BOGACZ, R., Gaik, M., URAM, E., MAGDA, I., Womperski, K., & OSUCH, M. (2023). use of psilocybin in the treatment of psychiatric disorders – review. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2023.43.01.009
632. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
633. Yan, Z. Y. Z. (2006). 非典型抗精神病药物在谵妄治疗中的进展. Zhonghua xingwei yixue yu naokexue zazhi. https://doi.org/10.3760/cma.j.issn.1005-8559.2006.07.046
634. Yanti, L., Andari, F. N., Novriadi, D., & Ferasinta, F. (2022). PENURUNAN INSOMNIA PADA LANSIA DENGAN TERAPI ZIKIR. Jurnal Pengabdian Masyarakat Bumi Raflesia. https://doi.org/10.36085/jpmbr.v5i3.3859
635. Yasui‐Furukori, N., & Kaneko, S. (2011). Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02211.x
636. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
637. Yee, B. J., Liu, P. Y., Phillips, C. L., & Grunstein, R. R. (2013). Neuroendocrine aspects of sleep apnea. CRC Press eBooks. https://doi.org/10.3109/9781420020885-16
638. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
639. Yui, K., Kajii, Y., & Nishikawa, T. (2006). Neurobiological and Molecular Bases of Methamphetamine-Induced Behavioral Sensitization and Spontaneous Recurrence of Methamphetamine Psychosis, and its Implication in Schizophrenia. Current Psychiatry Reviews. https://doi.org/10.2174/157340006778018111
640. Yıldız, M., Demirci, K., & Demirci, S. (2014). Recurring Psychogenic Aphonia: A Case Report. Abant Medical Journal. https://doi.org/10.5505/abantmedj.2014.82574
641. Zareifopoulos, N., & Panayiotakopoulos, G. (2019). Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence. Cureus. https://doi.org/10.7759/cureus.6152
642. Zawilska, J. B., Woldan‐Tambor, A., Płocka, A., Kużajska, K., & Wojcieszak, J. (2012). Narcolepsy: etiology, clinical features, diagnosis and treatment. Postępy Higieny i Medycyny Doświadczalnej. https://doi.org/10.5604/17322693.1015529
643. Zhang, J., & Zhou, X.-Z. (2014). Recent advance in nonconvulsive status epilepticus. Chinese Journal of Neuromedicine. https://doi.org/10.3760/cma.j.issn.1671-8925.2014.04.026
644. Ziégler, M. (2006). [Advanced Parkinson's disease].. PubMed.
645. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
646. Šostar, Z., Vodanović, M., Breitenfeld, D., Breitenfeld, T., Buljan, D., & Granić, R. (2009). Composers - Substance Abusers. Alcoholism and psychiatry research Journal on psychiatric research and addictions.